Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza‐decaline scaffold
Identifieur interne : 000E56 ( Pmc/Corpus ); précédent : 000E55; suivant : 000E57Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza‐decaline scaffold
Auteurs : Kenta Teruya ; Yasunao Hattori ; Yasuhiro Shimamoto ; Kazuya Kobayashi ; Akira Sanjoh ; Atsushi Nakagawa ; Eiki Yamashita ; Kenichi AkajiSource :
- Biopolymers [ 0006-3525 ] ; 2016.
Abstract
Design of inhibitors against severe acute respiratory syndrome (SARS) chymotrypsin‐like protease (3CLpro) is a potentially important approach to fight against SARS. We have developed several synthetic inhibitors by structure‐based drug design. In this report, we reveal two crystal structures of SARS 3CLpro complexed with two new inhibitors based on our previous work. These structures combined with six crystal structures complexed with a series of related ligands reported by us are collectively analyzed. To these eight complexes, the structural basis for inhibitor binding was analyzed by the COMBINE method, which is a chemometrical analysis optimized for the protein–ligand complex. The analysis revealed that the first two latent variables gave a cumulative contribution ratio of r2 = 0.971. Interestingly, scores using the second latent variables for each complex were strongly correlated with root mean square deviations (RMSDs) of side‐chain heavy atoms of Met49 from those of the intact crystal structure of SARS‐3CLpro (r = 0.77) enlarging the S2 pocket. The substantial contribution of this side chain (∼10%) for the explanation of pIC50s was dependent on stereochemistry and the chemical structure of the ligand adapted to the S2 pocket of the protease. Thus, starting from a substrate mimic inhibitor, a design for a central scaffold for a low molecular weight inhibitor was evaluated to develop a further potent inhibitor. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 391–403, 2016.
Url:
DOI: 10.1002/bip.22773
PubMed: 26572934
PubMed Central: 7159131
Links to Exploration step
PMC:7159131Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an <italic>aza</italic>
‐decaline scaffold</title>
<author><name sortKey="Teruya, Kenta" sort="Teruya, Kenta" uniqKey="Teruya K" first="Kenta" last="Teruya">Kenta Teruya</name>
<affiliation><nlm:aff id="bip22773-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hattori, Yasunao" sort="Hattori, Yasunao" uniqKey="Hattori Y" first="Yasunao" last="Hattori">Yasunao Hattori</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Shimamoto, Yasuhiro" sort="Shimamoto, Yasuhiro" uniqKey="Shimamoto Y" first="Yasuhiro" last="Shimamoto">Yasuhiro Shimamoto</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kobayashi, Kazuya" sort="Kobayashi, Kazuya" uniqKey="Kobayashi K" first="Kazuya" last="Kobayashi">Kazuya Kobayashi</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sanjoh, Akira" sort="Sanjoh, Akira" uniqKey="Sanjoh A" first="Akira" last="Sanjoh">Akira Sanjoh</name>
<affiliation><nlm:aff id="bip22773-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nakagawa, Atsushi" sort="Nakagawa, Atsushi" uniqKey="Nakagawa A" first="Atsushi" last="Nakagawa">Atsushi Nakagawa</name>
<affiliation><nlm:aff id="bip22773-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Yamashita, Eiki" sort="Yamashita, Eiki" uniqKey="Yamashita E" first="Eiki" last="Yamashita">Eiki Yamashita</name>
<affiliation><nlm:aff id="bip22773-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Akaji, Kenichi" sort="Akaji, Kenichi" uniqKey="Akaji K" first="Kenichi" last="Akaji">Kenichi Akaji</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">26572934</idno>
<idno type="pmc">7159131</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159131</idno>
<idno type="RBID">PMC:7159131</idno>
<idno type="doi">10.1002/bip.22773</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000E56</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an <italic>aza</italic>
‐decaline scaffold</title>
<author><name sortKey="Teruya, Kenta" sort="Teruya, Kenta" uniqKey="Teruya K" first="Kenta" last="Teruya">Kenta Teruya</name>
<affiliation><nlm:aff id="bip22773-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hattori, Yasunao" sort="Hattori, Yasunao" uniqKey="Hattori Y" first="Yasunao" last="Hattori">Yasunao Hattori</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Shimamoto, Yasuhiro" sort="Shimamoto, Yasuhiro" uniqKey="Shimamoto Y" first="Yasuhiro" last="Shimamoto">Yasuhiro Shimamoto</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kobayashi, Kazuya" sort="Kobayashi, Kazuya" uniqKey="Kobayashi K" first="Kazuya" last="Kobayashi">Kazuya Kobayashi</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sanjoh, Akira" sort="Sanjoh, Akira" uniqKey="Sanjoh A" first="Akira" last="Sanjoh">Akira Sanjoh</name>
<affiliation><nlm:aff id="bip22773-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nakagawa, Atsushi" sort="Nakagawa, Atsushi" uniqKey="Nakagawa A" first="Atsushi" last="Nakagawa">Atsushi Nakagawa</name>
<affiliation><nlm:aff id="bip22773-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Yamashita, Eiki" sort="Yamashita, Eiki" uniqKey="Yamashita E" first="Eiki" last="Yamashita">Eiki Yamashita</name>
<affiliation><nlm:aff id="bip22773-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Akaji, Kenichi" sort="Akaji, Kenichi" uniqKey="Akaji K" first="Kenichi" last="Akaji">Kenichi Akaji</name>
<affiliation><nlm:aff id="bip22773-aff-0002"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Biopolymers</title>
<idno type="ISSN">0006-3525</idno>
<idno type="eISSN">1097-0282</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>ABSTRACT</title>
<p>Design of inhibitors against severe acute respiratory syndrome (SARS) chymotrypsin‐like protease (3CL<sup>pro</sup>
) is a potentially important approach to fight against SARS. We have developed several synthetic inhibitors by structure‐based drug design. In this report, we reveal two crystal structures of SARS 3CL<sup>pro</sup>
complexed with two new inhibitors based on our previous work. These structures combined with six crystal structures complexed with a series of related ligands reported by us are collectively analyzed. To these eight complexes, the structural basis for inhibitor binding was analyzed by the COMBINE method, which is a chemometrical analysis optimized for the protein–ligand complex. The analysis revealed that the first two latent variables gave a cumulative contribution ratio of r<sup>2</sup>
= 0.971. Interestingly, scores using the second latent variables for each complex were strongly correlated with root mean square deviations (RMSDs) of side‐chain heavy atoms of Met<sup>49</sup>
from those of the intact crystal structure of SARS‐3CL<sup>pro</sup>
(r = 0.77) enlarging the S<sub>2</sub>
pocket. The substantial contribution of this side chain (∼10%) for the explanation of pIC<sub>50</sub>
s was dependent on stereochemistry and the chemical structure of the ligand adapted to the S<sub>2</sub>
pocket of the protease. Thus, starting from a substrate mimic inhibitor, a design for a central scaffold for a low molecular weight inhibitor was evaluated to develop a further potent inhibitor. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 391–403, 2016.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Biopolymers</journal-id>
<journal-id journal-id-type="iso-abbrev">Biopolymers</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)1097-0282a</journal-id>
<journal-id journal-id-type="publisher-id">BIP</journal-id>
<journal-title-group><journal-title>Biopolymers</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3525</issn>
<issn pub-type="epub">1097-0282</issn>
<publisher><publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">26572934</article-id>
<article-id pub-id-type="pmc">7159131</article-id>
<article-id pub-id-type="doi">10.1002/bip.22773</article-id>
<article-id pub-id-type="publisher-id">BIP22773</article-id>
<article-categories><subj-group subj-group-type="overline"><subject>Article</subject>
</subj-group>
<subj-group subj-group-type="heading"><subject>Articles</subject>
</subj-group>
</article-categories>
<title-group><article-title>Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an <italic>aza</italic>
‐decaline scaffold</article-title>
<alt-title alt-title-type="focus-section">Peptide Science</alt-title>
<alt-title alt-title-type="right-running-head">Development of SARS 3CL Protease Inhibitors</alt-title>
<alt-title alt-title-type="left-running-head">Teruya et al.</alt-title>
</title-group>
<contrib-group><contrib id="bip22773-cr-0001" contrib-type="author" corresp="yes"><name><surname>Teruya</surname>
<given-names>Kenta</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0001"><sup>1</sup>
</xref>
</contrib>
<contrib id="bip22773-cr-0002" contrib-type="author"><name><surname>Hattori</surname>
<given-names>Yasunao</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0002"><sup>2</sup>
</xref>
</contrib>
<contrib id="bip22773-cr-0003" contrib-type="author"><name><surname>Shimamoto</surname>
<given-names>Yasuhiro</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0002"><sup>2</sup>
</xref>
</contrib>
<contrib id="bip22773-cr-0004" contrib-type="author"><name><surname>Kobayashi</surname>
<given-names>Kazuya</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0002"><sup>2</sup>
</xref>
</contrib>
<contrib id="bip22773-cr-0005" contrib-type="author"><name><surname>Sanjoh</surname>
<given-names>Akira</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0003"><sup>3</sup>
</xref>
</contrib>
<contrib id="bip22773-cr-0006" contrib-type="author"><name><surname>Nakagawa</surname>
<given-names>Atsushi</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0004"><sup>4</sup>
</xref>
</contrib>
<contrib id="bip22773-cr-0007" contrib-type="author"><name><surname>Yamashita</surname>
<given-names>Eiki</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0004"><sup>4</sup>
</xref>
</contrib>
<contrib id="bip22773-cr-0008" contrib-type="author" corresp="yes"><name><surname>Akaji</surname>
<given-names>Kenichi</given-names>
</name>
<xref ref-type="aff" rid="bip22773-aff-0002"><sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bip22773-aff-0001"><label><sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Neurochemistry</named-content>
<institution>Tohoku University Graduate School of Medicine</institution>
<city>Aoba‐Ku Sendai</city>
<postal-code>980‐8575</postal-code>
<country country="JP">Japan</country>
</aff>
<aff id="bip22773-aff-0002"><label><sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medicinal Chemistry</named-content>
<institution>Kyoto Pharmaceutical University</institution>
<city>Yamashina‐Ku</city>
<named-content content-type="country-part">Kyoto</named-content>
<postal-code>607‐8412</postal-code>
<country country="JP">Japan</country>
</aff>
<aff id="bip22773-aff-0003"><label><sup>3</sup>
</label>
<institution>R&D Center, Protein Wave Co</institution>
<city>Nara</city>
<postal-code>631‐0006</postal-code>
<country country="JP">Japan</country>
</aff>
<aff id="bip22773-aff-0004"><label><sup>4</sup>
</label>
<institution>Institute for Protein Research, Osaka University</institution>
<city>Suita</city>
<named-content content-type="country-part">Osaka</named-content>
<postal-code>565‐0871</postal-code>
<country country="JP">Japan</country>
</aff>
<author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence to: Kenta Teruya, Division of Neurochemistry, Tohoku University Graduate School of Medicine, 2‐1 Seiryo, Aoba, Sendai 980‐8575, Japan; e‐mail: <email>kenta.teruya.d4@tohoku.ac.jp</email>
and Kenichi Akaji, Department of Medicinal Chemistry, Kyoto Pharmaceutical University, Yamashina‐ku, Kyoto 607‐8412, Japan; e‐mail: <email>akaji@mb.kyoto-phu.ac.jp</email>
</corresp>
</author-notes>
<pub-date pub-type="epub"><day>22</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub"><month>7</month>
<year>2016</year>
</pub-date>
<volume>106</volume>
<issue>4</issue>
<issue-id pub-id-type="doi">10.1002/bip.v106.4</issue-id>
<issue-id pub-id-type="focus-section-id">1</issue-id>
<issue-title content-type="special-issue-title">Emerging Peptide Science from Japan</issue-title>
<fpage>391</fpage>
<lpage>403</lpage>
<history><date date-type="received"><day>31</day>
<month>8</month>
<year>2015</year>
</date>
<date date-type="rev-recd"><day>22</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="accepted"><day>02</day>
<month>11</month>
<year>2015</year>
</date>
</history>
<permissions><pmc-comment> © 2016 Wiley Periodicals, Inc. </pmc-comment>
<copyright-statement content-type="article-copyright">© 2015 Wiley Periodicals, Inc.</copyright-statement>
<license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BIP-106-391.pdf"></self-uri>
<abstract><title>ABSTRACT</title>
<p>Design of inhibitors against severe acute respiratory syndrome (SARS) chymotrypsin‐like protease (3CL<sup>pro</sup>
) is a potentially important approach to fight against SARS. We have developed several synthetic inhibitors by structure‐based drug design. In this report, we reveal two crystal structures of SARS 3CL<sup>pro</sup>
complexed with two new inhibitors based on our previous work. These structures combined with six crystal structures complexed with a series of related ligands reported by us are collectively analyzed. To these eight complexes, the structural basis for inhibitor binding was analyzed by the COMBINE method, which is a chemometrical analysis optimized for the protein–ligand complex. The analysis revealed that the first two latent variables gave a cumulative contribution ratio of r<sup>2</sup>
= 0.971. Interestingly, scores using the second latent variables for each complex were strongly correlated with root mean square deviations (RMSDs) of side‐chain heavy atoms of Met<sup>49</sup>
from those of the intact crystal structure of SARS‐3CL<sup>pro</sup>
(r = 0.77) enlarging the S<sub>2</sub>
pocket. The substantial contribution of this side chain (∼10%) for the explanation of pIC<sub>50</sub>
s was dependent on stereochemistry and the chemical structure of the ligand adapted to the S<sub>2</sub>
pocket of the protease. Thus, starting from a substrate mimic inhibitor, a design for a central scaffold for a low molecular weight inhibitor was evaluated to develop a further potent inhibitor. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 391–403, 2016.</p>
</abstract>
<kwd-group kwd-group-type="author-generated"><kwd id="bip22773-kwd-0001">SARS 3CL protease</kwd>
<kwd id="bip22773-kwd-0002">inhibitor</kwd>
<kwd id="bip22773-kwd-0003">aza‐decaline</kwd>
<kwd id="bip22773-kwd-0004">SARS 3CL protease</kwd>
<kwd id="bip22773-kwd-0005">crystal structure complexed with inhibitor</kwd>
<kwd id="bip22773-kwd-0006">aza‐decaline scaffold</kwd>
<kwd id="bip22773-kwd-0007">COMBINE analysis for inhibitor design, hydrophobic interaction</kwd>
</kwd-group>
<funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Japan Society for the Promotion of Science
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100001691</institution-id>
</institution-wrap>
</funding-source>
<award-id>23550195</award-id>
<award-id>25460160</award-id>
</award-group>
<award-group id="funding-0002"><funding-source><institution-wrap><institution>Adaptable and Seamless Technology Transfer Program through Target‐driven R&D from Japan Science and Technology Agency
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100002241</institution-id>
</institution-wrap>
</funding-source>
<award-id>AS251Z01976Q
</award-id>
</award-group>
</funding-group>
<counts><page-count count="13"></page-count>
</counts>
<custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta><meta-name>cover-date</meta-name>
<meta-value>July 2016</meta-value>
</custom-meta>
<custom-meta><meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:15.04.2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes notes-type="dedication"><p>This paper is dedicated to Emeritus Professor Haruaki Yajima on the occasion of his 90th birthday.</p>
</notes>
<notes><fn-group><fn id="bip22773-note-0002"><p>This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of any preprints from the past two calendar years by emailing the Biopolymers editorial office at <email>biopolymers@wiley.com</email>
.</p>
</fn>
</fn-group>
</notes>
</front>
<body><sec id="bip22773-sec-0001"><title>INTRODUCTION</title>
<p>Although the primary epidemic of severe acute respiratory syndrome (SARS)<xref rid="bip22773-bib-0001" ref-type="ref">1</xref>
, <xref rid="bip22773-bib-0002" ref-type="ref">2</xref>
, <xref rid="bip22773-bib-0003" ref-type="ref">3</xref>
was eventually brought under control, the recent identification of a SARS CoV (coronavirus)‐like virus in Chinese bats<xref rid="bip22773-bib-0004" ref-type="ref">4</xref>
, <xref rid="bip22773-bib-0005" ref-type="ref">5</xref>
indicates that there are natural reservoirs for this virus. Since no effective therapy exists for these viral infections, developing anti‐SARS agents against future outbreaks remains a formidable challenge. In the early stage of the infection, SARS 3CL protease (3CL<sup>pro</sup>
) is a key enzyme to cleave polyproteins to yield functional polypeptides for replication.<xref rid="bip22773-bib-0006" ref-type="ref">6</xref>
, <xref rid="bip22773-bib-0007" ref-type="ref">7</xref>
The 3CL<sup>pro</sup>
is a cysteine protease containing a Cys‐His catalytic dyad. Because of its functional importance in the viral lifecycle, 3CL<sup>pro</sup>
is considered an attractive target for the structure‐based design of drugs against SARS. Thus, numerous inhibitors of 3CL<sup>pro</sup>
have been reported including peptide‐mimics<xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
, <xref rid="bip22773-bib-0009" ref-type="ref">9</xref>
, <xref rid="bip22773-bib-0010" ref-type="ref">10</xref>
, <xref rid="bip22773-bib-0011" ref-type="ref">11</xref>
, <xref rid="bip22773-bib-0012" ref-type="ref">12</xref>
and small molecules derived from natural products,<xref rid="bip22773-bib-0013" ref-type="ref">13</xref>
, <xref rid="bip22773-bib-0014" ref-type="ref">14</xref>
, <xref rid="bip22773-bib-0015" ref-type="ref">15</xref>
anti‐viral agents,<xref rid="bip22773-bib-0016" ref-type="ref">16</xref>
, <xref rid="bip22773-bib-0017" ref-type="ref">17</xref>
anti‐malaria agents,<xref rid="bip22773-bib-0018" ref-type="ref">18</xref>
or high throughput screening.<xref rid="bip22773-bib-0019" ref-type="ref">19</xref>
, <xref rid="bip22773-bib-0020" ref-type="ref">20</xref>
, <xref rid="bip22773-bib-0021" ref-type="ref">21</xref>
, <xref rid="bip22773-bib-0022" ref-type="ref">22</xref>
</p>
<p>In the course of our own studies on SARS 3CL<sup>pro</sup>
and its inhibitors,<xref rid="bip22773-bib-0023" ref-type="ref">23</xref>
we found that mature SARS 3CL<sup>pro</sup>
is sensitive to degradation at the 188Arg/189Gln site, and the Arg188Ile mutant is resistant to this degradation. As a result, this stable mutant protease makes it feasible for evaluating designed and synthesized inhibitors. Exploring useful inhibitors for SARS 3CL<sup>pro</sup>
based on the substrate revealed that peptide aldehyde is a facile for designing an inhibitor for SARS 3CL<sup>pro</sup>
. Through combinations of the systematic substitution of peptide aldehyde amino acid and the crystallographic analysis of the complexes, a leading inhibitor (Table <xref rid="bip22773-tbl-0001" ref-type="table">1</xref>
, entry <bold>1</bold>
) emerged. This peptide‐based inhibitor has all of its side‐chain structures differing from the substrate non‐prime site sequence, Thr‐Ser‐Ala‐Val‐Leu‐Gln, except at the P<sub>3</sub>
site where the side‐chain was directed outward. Especially, substitution of Leu to cyclohexyl alanine (Cha) P<sub>2</sub>
of the peptide inhibitor gave a higher increase in inhibitory potency to SARS 3CL<sup>pro</sup>
(Table <xref rid="bip22773-tbl-0001" ref-type="table">1</xref>
, entries <bold>1</bold>
and <bold>2</bold>
). Moreover, crystallographic analysis of the inhibitor complex provided an extended design of both deletion at the P<sub>5</sub>
residue and mutation providing a hetero atom at the P<sub>4</sub>
position of the inhibitor. Evaluation of IC<sub>50</sub>
in the protease and crystallographic analysis revealed that this down size design was clearly realized without any substantial decrease in potency (Table <xref rid="bip22773-tbl-0001" ref-type="table">1</xref>
, entry <bold>3</bold>
).</p>
<table-wrap id="bip22773-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label>
<caption><p>Data Set of the Properties of an Inhibitor Co‐crystallized With 3CL<sup>pro</sup>
</p>
</caption>
<table frame="hsides" rules="groups"><col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Compound entry No.</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Chemical Structure of Ligand</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Complex PDB Code</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">pIC<sub>50</sub>
</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Reference</th>
</tr>
</thead>
<tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>1</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-1" xlink:href="BIP-106-391-g010"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3AW0</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">5.244</td>
<td align="left" valign="top" rowspan="1" colspan="1"><xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>2</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-3" xlink:href="BIP-106-391-g011"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3AVZ</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">7.187</td>
<td align="left" valign="top" rowspan="1" colspan="1"><xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>3</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-5" xlink:href="BIP-106-391-g012"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3ATW</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">7.009</td>
<td align="left" valign="top" rowspan="1" colspan="1"><xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>4</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-7" xlink:href="BIP-106-391-g013"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">4WY3</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">3.620</td>
<td align="left" valign="top" rowspan="1" colspan="1"><xref rid="bip22773-bib-0024" ref-type="ref">24</xref>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>5</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-9" xlink:href="BIP-106-391-g014"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">4TWY</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">3.967</td>
<td align="left" valign="top" rowspan="1" colspan="1"><xref rid="bip22773-bib-0024" ref-type="ref">24</xref>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>6</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-11" xlink:href="BIP-106-391-g015"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">4TWW</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">4.201</td>
<td align="left" valign="top" rowspan="1" colspan="1"><xref rid="bip22773-bib-0024" ref-type="ref">24</xref>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>7</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-13" xlink:href="BIP-106-391-g016"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">5C5O</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">3.668</td>
<td align="left" valign="top" rowspan="1" colspan="1">This work</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>8</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><graphic id="nlm-graphic-15" xlink:href="BIP-106-391-g017"></graphic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">5C5N</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">3.561</td>
<td align="left" valign="top" rowspan="1" colspan="1">This work</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>9</bold>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">–</td>
<td align="center" valign="top" rowspan="1" colspan="1">3AW1</td>
<td align="left" valign="top" rowspan="1" colspan="1">–</td>
<td align="left" valign="top" rowspan="1" colspan="1"><xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Based on this wide range surveillance of the surroundings of the active sites by the peptide aldehyde inhibitor, a novel non‐peptide inhibitor based on interactions at the S<sub>1</sub>
and S<sub>2</sub>
sites of SARS 3CL<sup>pro</sup>
was designed and synthesized.<xref rid="bip22773-bib-0024" ref-type="ref">24</xref>
In the study, focusing on the fact that P<sub>1</sub>
and P<sub>2</sub>
sites interact with the catalytic dyad and hydrophobic pocket, respectively, compounds were designed by connecting the P<sub>2</sub>
site cyclohexyl group of the substrate‐based inhibitor to the main‐chain at α−nitrogen atom of the P<sub>2</sub>
position Cha via a methylene linker. This strategy gave <italic>aza</italic>
‐decaline as a central scaffold of the inhibitor with expected restricted conformational diversity of the P<sub>2</sub>
site. The designed compounds showed substantial inhibitory activity. By X‐ray crystallographic studies (Figure <xref rid="bip22773-fig-0001" ref-type="fig">1</xref>
), it was confirmed that the <italic>aza</italic>
‐decaline inhibitors were at the active site cleft of 3CL<sup>pro</sup>
and the <italic>aza</italic>
‐decaline scaffold was inserted into a large S<sub>2</sub>
pocket, while most of the S<sub>2</sub>
pocket was occupied. Interestingly, the stereochemistry on the <italic>aza</italic>
‐decaline scaffold, (4a<italic>S</italic>
,8a<italic>R</italic>
) and (4a<italic>R</italic>
,8a<italic>S</italic>
), showed clear differences in inhibitory activities for SARS 3CL<sup>pro</sup>
(Table <xref rid="bip22773-tbl-0001" ref-type="table">1</xref>
entries <bold>4</bold>
‐<bold>6</bold>
). Thus, starting from the substrate mimic peptide aldehyde as a leading compound, we have been developing nonpeptidic inhibitors by extracting fine structure–activity relationships from these crystallographic analyses. However, this stereostructure–activity relationship was not fully evaluated because of a shortage of samples for structural comparison.</p>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0001" orientation="portrait" position="float"><label>Figure 1</label>
<caption><p>(A) The catalytic site of 3CL<sup>pro</sup>
. Six structures containing inhibitors <bold>1</bold>
‐<bold>6</bold>
were superimposed. The inhibitors are shown in the stick model. The S<sub>2</sub>
pocket is located at approximately the middle position along the direction of depth. The P<sub>3</sub>
and P<sub>4</sub>
of peptide‐based inhibitors <bold>1</bold>
‐<bold>3</bold>
are extended to the left along with the groove, while <italic>N</italic>
‐acyl‐parts of an <italic>aza</italic>
‐decaline based inhibitor are directed outward. (B) Schematic drawing of <italic>aza</italic>
‐decaline‐based inhibitors <bold>4</bold>
‐<bold>8</bold>
. The basic structure was divided into three parts. Stereochemistry of positions 4a, 8a, and 3 and the structures of the <italic>N</italic>
‐acyl group are different among <bold>4</bold>
‐<bold>8</bold>
.</p>
</caption>
<graphic id="nlm-graphic-17" xlink:href="BIP-106-391-g001"></graphic>
</fig>
<p>The COMparative BINding Energy (COMBINE) method developed by Ortiz<xref rid="bip22773-bib-0025" ref-type="ref">25</xref>
is a powerful pipeline for the decomposition of the ligand–receptor interaction energies into a series of terms, extracting latent variables (LV) for the explanation of the interactions and then, assigning weights to selected ligand–residue interactions using multivariate statistics and partial least square (PLS) analysis to correlate with a set of ligand–receptor complexes data on the experimental activities or binding affinities. Gil‐Redondo and colleagues<xref rid="bip22773-bib-0026" ref-type="ref">26</xref>
developed gCOMBINE, which is a user‐friendly graphical interface, to perform the analysis with defined input files and sophisticated result presentations. Since the ligand‐induced structural alternation is taken into account, ligand–receptor interactions can be better understood by chemometrical analysis. This method has been applied to various analyses of quantitative structure–activity relationships.<xref rid="bip22773-bib-0027" ref-type="ref">27</xref>
, <xref rid="bip22773-bib-0028" ref-type="ref">28</xref>
, <xref rid="bip22773-bib-0029" ref-type="ref">29</xref>
, <xref rid="bip22773-bib-0030" ref-type="ref">30</xref>
, <xref rid="bip22773-bib-0031" ref-type="ref">31</xref>
, <xref rid="bip22773-bib-0032" ref-type="ref">32</xref>
, <xref rid="bip22773-bib-0033" ref-type="ref">33</xref>
, <xref rid="bip22773-bib-0034" ref-type="ref">34</xref>
, <xref rid="bip22773-bib-0035" ref-type="ref">35</xref>
, <xref rid="bip22773-bib-0036" ref-type="ref">36</xref>
, <xref rid="bip22773-bib-0037" ref-type="ref">37</xref>
, <xref rid="bip22773-bib-0038" ref-type="ref">38</xref>
, <xref rid="bip22773-bib-0039" ref-type="ref">39</xref>
, <xref rid="bip22773-bib-0040" ref-type="ref">40</xref>
, <xref rid="bip22773-bib-0041" ref-type="ref">41</xref>
.</p>
<p>To get further insight into the relations between the configuration of the side chain of the <italic>aza</italic>
‐decaline scaffold and the structure of the complexes, we analyzed two new complexes in which the ligands were (4a<italic>S</italic>
,8a<italic>R</italic>
)‐ and (4a<italic>R</italic>
,8a<italic>S</italic>
)‐ <italic>aza</italic>
‐decaline scaffold. Then, these structures and our previously reported six crystal structures of a complex with a series of ligands and one crystal structure without ligands were collectively referred to derive a quantitative model.</p>
</sec>
<sec id="bip22773-sec-0002"><title>MATERIALS AND METHODS</title>
<p>In the present study, two inhibitors were newly synthesized and examined for their inhibitory activity. These inhibitors were complexed with SARS 3CL<sup>pro</sup>
and the complexes were subjected to X‐ray structural analysis. After these structural analyses, another six complex structures containing previously developed inhibitors were subjected to the gCOMBINE, a chemometric analysis. Table <xref rid="bip22773-tbl-0001" ref-type="table">1</xref>
shows the chemical structures, PDB IDs, and the properties of the inhibitors.</p>
<sec id="bip22773-sec-0003"><title>Synthesis and Determination of Inhibitory Activity of Compounds 7 and 8</title>
<p>Inhibitors <bold>7</bold>
and <bold>8</bold>
were synthesized based on the Scheme <xref rid="bip22773-fig-0009" ref-type="fig">1</xref>
as previously described with modifications. Briefly, starting from an enantio‐mixture of alcohol <bold>a</bold>
, previously reported product<xref rid="bip22773-bib-0024" ref-type="ref">24</xref>
by Diels‐Alder reaction, the primary alcohol was converted to azide and then the amino group (<bold>b</bold>
). Amine <bold>b</bold>
was condensed with <italic>N</italic>
‐Boc‐<italic>N</italic>
‐phenyl β‐alanine (Ph‐(Boc)bAla) to afford an enantio‐mixture of compound <bold>c</bold>
, a precursor of the cyclization reaction. Amide <bold>c</bold>
, in which the nitrogen of the amide group located at 5‐carbon apart from olefin, was cyclized with a Pd‐based catalysis.<xref rid="bip22773-bib-0042" ref-type="ref">42</xref>
The obtained enantio‐mixture of an <italic>aza‐</italic>
decaline derivative, olefin <bold>d</bold>
was converted to diol and then to aldehyde by Lemieux‐Johnson oxidation. The resulting <italic>aza</italic>
‐decaline‐derived aldehyde and H‐His(Trt)‐N(CH<sub>3</sub>
)OCH<sub>3</sub>
were condensed via reductive amination to give a diastereo‐mixture of compound <bold>e</bold>
. This diastereo‐mixture was separated and purified by flash column chromatography into <bold>7e</bold>
and <bold>8e</bold>
corresponding in stereochemistry to <bold>7</bold>
and <bold>8</bold>
, respectively. Trt and Boc groups of <bold>7e</bold>
and <bold>8e</bold>
were removed and purified by a silica column. Finally, Weinreb amides were converted to aldehyde and then purified by RP‐HPLC. Yields were 3% and 1% for <bold>7</bold>
and <bold>8</bold>
, respectively, based on the enantio‐mixture of olefin <bold>d</bold>
.</p>
<p>For measurements of IC<sub>50</sub>
s of compounds <bold>7</bold>
and <bold>8</bold>
, peptide substrate, H‐Thr‐Ser‐Ala‐Val‐Leu‐Gln‐Ser‐Gly‐Phe‐Arg‐Lys‐NH<sub>2</sub>
, (111 μM) in a reaction solution (25 μL of 20 m<italic>M</italic>
Tris‐HCl buffer pH7.5 containing 7 m<italic>M</italic>
DTT) was incubated with the R188I SARS 3CL<sup>pro</sup>
(56 nM)<xref rid="bip22773-bib-0023" ref-type="ref">23</xref>
at 37°C for 60 min in the presence of various inhibitor concentrations at 37°C for 60 min. The cleavage reaction was monitored by analytical HPLC, a linear gradient of CH<sub>3</sub>
CN (10‐20%) in an aq. 0.1% TFA over 30 min, and the cleavage rates were calculated from the decrease in the substrate peak area. Each IC<sub>50</sub>
value was obtained from the sigmoidal dose–response curve. The chemical structure and potency are listed in Table <xref rid="bip22773-tbl-0001" ref-type="table">1</xref>
.</p>
<p>Compound <bold>7e</bold>
: [α]<sup>28</sup>
<sub>D</sub>
−63.6 (<italic>c</italic>
1.1, CHCl<sub>3</sub>
); <sup>1</sup>
H NMR (400 MHz): δ = 7.40‐7.06 (m, 20H), 6.58‐6.55 (s, 2H), 4.71‐4.66 (m, 1H), 4.33‐4.30 (m, 1H), 4.01‐3.82 (m, 4H), 3.60 (s, 2H), 3.53 (s, 1H), 3.09 (s, 3H), 2.81‐2.56 (m, 4H), 2.44‐2.39 (m, 1H), 2.17‐2.11 (m, 1H), 1.75‐1.47 (m, 7H), 1.42 (s, 9H), 1.37‐0.84 (m, 4H); <sup>13</sup>
C NMR (100 MHz): δ = 169.8, 169.2, 154.5, 154.4, 142.51, 142.46, 142.39, 140.3, 138.2, 138.0, 137.7, 137.3, 129.74, 129.71, 128.9, 128.68, 128.64, 128.54, 127.92, 127.90, 127.85, 126.89, 126.85, 125.95, 125.85, 119.3, 119.2, 80.2, 80.1, 77.2, 75.02, 75.0, 61.5, 57.8, 57.5, 53.7, 47.8, 47.3, 47.1, 47.07, 47.04, 46.2, 42.4, 41.7, 36.1, 36.0, 34.2, 32.89, 32.88, 32.6, 32.4, 32.1, 31.9, 29.8, 29.6, 28.3, 26.1, 25.8, 25.7,; HRMS (EI) Calcd. For C<sub>51</sub>
H<sub>62</sub>
N<sub>6</sub>
O<sub>5</sub>
[M]<sup>+</sup>
: 838.4782. Found: 838.4787.</p>
<p>Compound <bold>8e</bold>
: [α]<sup>26</sup>
<sub>D</sub>
−174 (<italic>c</italic>
0.33, CHCl<sub>3</sub>
); <sup>1</sup>
H NMR (400 MHz): δ = 7.38‐7.36 (m, 6H), 7.34‐7.25 (m, 9H), 7.20‐7.13 (m, 5H), 7.08‐7.06 (m, 2H), 4.90‐4.62 (m, 1H), 3.87‐3.77 (m, 3H), 3.64‐3.41 (m, 4H), 3.19 (s, 3H), 3.01‐2.30 (m, 7H), 1.73‐1.55 (m, 3H), 1.38 (d, 5.6 Hz, 9H), 1.32‐0.84 (m, 8H); <sup>13</sup>
C NMR (100 MHz): δ = 169.9, 169.4, 154.5, 142.5, 142.4, 138.2, 138.0, 137.5, 137.3, 129.7, 128.7, 128.6, 127.92, 127.89, 127.84, 126.9, 126.8, 125.92, 125.85, 119.2, 80.2, 80.1, 77.2, 75.01, 75.00, 61.5, 58.0, 57.7, 53.9, 42.6, 42.2, 41.7, 36.44, 36.37, 34.45, 33.4, 32.9, 32.6, 32.4, 32.3, 32.2, 29.8, 29.85, 29.80, 29.3, 28.3, 26.14, 26.08, 25.8, 25.7.; HRMS (EI) Calcd. For C<sub>51</sub>
H<sub>62</sub>
N<sub>6</sub>
O<sub>5</sub>
[M]<sup>+</sup>
: 838.4782. Found: 838.4773.</p>
<p>Compound <bold>7</bold>
: (<italic>S</italic>
)−2‐[({(3<italic>S</italic>
,4a<italic>R</italic>
,8a<italic>S</italic>
)−2‐[3‐(phenylamino)‐propan‐1‐carbonyl]decahydroisoquinolin‐3‐yl}methyl)amino]‐3‐(1H‐imidazol‐4‐yl)‐propanal</p>
<p><sup>1</sup>
H NMR (400 MHz): δ = 8.70 (s, 1H), 7.43 (m, 1H), 7.21‐7.17 (m, 2H), 6.80‐6.79 (m, 2H), 5.09 (m, 1H), 4.75‐4.64 (m, 2H), 3.71‐3.61 (m. 1H), 3.50‐3.46 (m, 2H), 3.21‐3.19 (m, 2H), 3.12‐3.12 (m, 2H), 2.91‐2.84 (m, 1H), 2.68‐2.62 (m, 1H), 1.74‐0.91 (m, 12H).; HRMS (EI) Calcd. For C<sub>25</sub>
H<sub>33</sub>
N<sub>5</sub>
O [M‐H<sub>2</sub>
O]<sup>+</sup>
: 419.2685. Found: 419.2689.</p>
<p>Compound <bold>8</bold>
: (<italic>S</italic>
)−2‐[({(3<italic>R</italic>
,4a<italic>S</italic>
,8a<italic>R</italic>
)−2‐[3‐(phenylamino)‐propan‐1‐carbonyl]decahydroisoquinolin‐3‐yl}methyl)amino]‐3‐(1H‐imidazol‐4‐yl)‐propanal</p>
<p><sup>1</sup>
H NMR (400 MHz): δ = 8.51 (s, 1H), 7.34‐7.33 (m, 1H), 7.17‐7.12 (m, 2H), 6.73‐6.68 (m, 2H), 5.10 (m, 1H), 4.75‐4.68 (m, 2H), 3.74‐3.51 (m. 1H), 3.48‐3.40 (m, 2H), 3.21‐3.19 (m, 2H), 3.18‐3.14 (m, 2H), 2.90‐2.76 (m, 1H), 2.64‐2.62 (m, 1H), 1.73‐0.91 (m, 12H).; HRMS (EI) Calcd. For C<sub>25</sub>
H<sub>33</sub>
N<sub>5</sub>
O [M‐H<sub>2</sub>
O]<sup>+</sup>
: 419.2685. Found: 419.2682.</p>
</sec>
<sec id="bip22773-sec-0004"><title>X‐Ray Crystallography</title>
<p>The purified SARS 3CL<sup>pro</sup>
in 20 m<italic>M</italic>
Bis‐Tris pH5.5, 10 m<italic>M</italic>
NaCl, and 1 m<italic>M</italic>
DTT was concentrated to 8 mg/mL.<xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
Crystals of SARS 3CL<sup>pro</sup>
were grown at 4°C using a sitting‐drop vapor diffusion method by mixing it with an equal volume of reservoir solution containing 100 m<italic>M</italic>
MES pH 6.2, 5‐10% PEG20000, and 5 m<italic>M</italic>
DTT. Cubic‐shaped crystals with dimensions of 0.3 mm × 0.3 mm × 0.3 mm grew within 3 days. The crystals were then soaked for 24 hours with a reservoir‐based solution of 100 m<italic>M</italic>
MES pH 6.2, 5‐8% PEG20000, and 5 m<italic>M</italic>
DTT containing 3 m<italic>M</italic>
of <bold>7</bold>
or <bold>8</bold>
. Crystals were then transferred into a cryobuffer of 100 m<italic>M</italic>
MES pH 6.2, 10% PEG20000, 5 m<italic>M</italic>
DTT, 15% ethylene glycol containing 3 m<italic>M</italic>
of <bold>7</bold>
or <bold>8</bold>
, and flash‐frozen in a nitrogen stream at 100 K. X‐ray diffraction data of SARS 3CL<sup>pro</sup>
in complexes with inhibitor <bold>7</bold>
or <bold>8</bold>
was collected with a SPring‐8, beamline BL44XU with a Rayonix MX300HE CCD detector at a wavelength of 0.900 Å. The structures of SARS 3CL<sup>pro</sup>
in complex with inhibitors were determined by molecular replacement using the Molrep<xref rid="bip22773-bib-0043" ref-type="ref">43</xref>
program with a R188I SARS 3CL<sup>pro</sup>
structure (PDB code 3AW1<xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
) as the search model. Rigid body refinement and subsequent restrained refinement protocols were performed with the program Refmac 5<xref rid="bip22773-bib-0044" ref-type="ref">44</xref>
of the CCP package.<xref rid="bip22773-bib-0045" ref-type="ref">45</xref>
The Coot program<xref rid="bip22773-bib-0046" ref-type="ref">46</xref>
was used for manual model rebuilding. Water molecules were added using Coot only after refinement of the protein structures had converged. Ligands generated on JLigand<xref rid="bip22773-bib-0047" ref-type="ref">47</xref>
software were directly built into the corresponding difference electron density, and the model was then subjected to an additional round of refinement. The figures of structural representation in this paper were generated on Pymol<xref rid="bip22773-bib-0048" ref-type="ref">48</xref>
or UCSF‐Chimera<xref rid="bip22773-bib-0049" ref-type="ref">49</xref>
software. Crystallographic data and results of refinement are summarized in Table <xref rid="bip22773-tbl-0002" ref-type="table">2</xref>
.</p>
<table-wrap id="bip22773-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label>
<caption><p>Data Collection and Refinement Statistics for 3CL<sup>pro</sup>
and Its Inhibitor in Complexes With Compounds 7 and 8</p>
</caption>
<table frame="hsides" rules="groups"><col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">PDB ID</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">5C5O</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">5C5N</th>
</tr>
</thead>
<tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Inhibitor name</td>
<td align="center" valign="top" rowspan="1" colspan="1"><bold>7</bold>
</td>
<td align="center" valign="top" rowspan="1" colspan="1"><bold>8</bold>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Space group</td>
<td align="center" valign="top" rowspan="1" colspan="1">C<sub>121</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">P<sub>1</sub>
</td>
</tr>
<tr><td colspan="3" align="left" valign="top" rowspan="1">Unit cell parameters</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Length <italic>a</italic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">107.80</td>
<td align="center" valign="top" rowspan="1" colspan="1">54.66</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Length <italic>b</italic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">82.09</td>
<td align="center" valign="top" rowspan="1" colspan="1">58.66</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Length <italic>c</italic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">53.27</td>
<td align="center" valign="top" rowspan="1" colspan="1">68.10</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Angle <italic>α</italic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">90</td>
<td align="center" valign="top" rowspan="1" colspan="1">93.73</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Angle <italic>β</italic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">104.35</td>
<td align="center" valign="top" rowspan="1" colspan="1">103.40</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Angle <italic>γ</italic>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">90</td>
<td align="center" valign="top" rowspan="1" colspan="1">106.51</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Resolution</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.65</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.50</td>
</tr>
<tr><td colspan="3" align="left" valign="top" rowspan="1">Observations</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Unique observations</td>
<td align="center" valign="top" rowspan="1" colspan="1">52746</td>
<td align="center" valign="top" rowspan="1" colspan="1">119208</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Redundancy</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.0</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.2</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Completeness</td>
<td align="center" valign="top" rowspan="1" colspan="1">84.8</td>
<td align="center" valign="top" rowspan="1" colspan="1">95.0</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Mean I/sigma(I)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.41 (at 1.65 Å)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.36 (at 1.50 Å)</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>R</italic>
<sub>merge</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.08</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.06</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Resolution range</td>
<td align="center" valign="top" rowspan="1" colspan="1">37.59–1.69</td>
<td align="center" valign="top" rowspan="1" colspan="1">30.2–1.50</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>R</italic>
<sub>cryst</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.29</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.25</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>R</italic>
<sub>free</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.32</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.27</td>
</tr>
<tr><td colspan="3" align="left" valign="top" rowspan="1">RMSZ from ideal</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Bond length</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.87</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.99</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Bond angle</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.92</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.01</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="bip22773-sec-0005"><title>gCOMBINE Analysis</title>
<p>PDB<xref rid="bip22773-bib-0050" ref-type="ref">50</xref>
files of the complex (corresponding to PDB ID: 3AW0, 3AVZ, 3ATW, 4TWY, 4TWW, 4WY3, 5C5O and 5C5N)<xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
, <xref rid="bip22773-bib-0024" ref-type="ref">24</xref>
were prepared as containing a single complex with a ligand. The complexes were imposed on the structure of SARS 3CL<sup>pro</sup>
without a ligand (PDB ID: 3AW1<xref rid="bip22773-bib-0008" ref-type="ref">8</xref>
) on the Match‐Maker<xref rid="bip22773-bib-0051" ref-type="ref">51</xref>
program based on the main chain Cα of the protease. Each complex was protonated and minimized under an amberFF14SB<xref rid="bip22773-bib-0052" ref-type="ref">52</xref>
force field powered by MMTK<xref rid="bip22773-bib-0053" ref-type="ref">53</xref>
and inhibitors were assigned AM1‐BCC charges<xref rid="bip22773-bib-0054" ref-type="ref">54</xref>
and fully optimized at the AM1 level using the MOPAC program<xref rid="bip22773-bib-0055" ref-type="ref">55</xref>
on UCSF‐Chimera.<xref rid="bip22773-bib-0049" ref-type="ref">49</xref>
The proteases and inhibitors were saved separately.</p>
<p>The parametrization for the gCOMBINE<xref rid="bip22773-bib-0026" ref-type="ref">26</xref>
was performed on the tLEaP module in AMBERTOOL14 program<xref rid="bip22773-bib-0056" ref-type="ref">56</xref>
suits. The PDB files of the receptor protease were cleaned by pdb4amber.<xref rid="bip22773-bib-0057" ref-type="ref">57</xref>
The antechamber suite<xref rid="bip22773-bib-0058" ref-type="ref">58</xref>
has been developed to be used with the general AMBER force field for small molecules. The PDB files of the inhibitor were converted to mol2 files by antechamber, and frcmod and lib files for each inhibitor were generated by parmchk. Each file of the protease and inhibitor was combined and neutrized. For each complex, parameter and topology files were generated.</p>
<p>The COMBINE program was used to decompose the interaction energy between the inhibitor and protein in each complex. That is, this program was used to calculate the Lennard‐Jones and electrostatic interactions between the inhibitor and each protein residue on a per residue basis. gCOMBINE is a graphical interface that runs COMBINE. The gCOMBINE automatically arranges and constructs an <bold>X</bold>
matrix in which the rows represent the different compounds studied, and the columns contain the residue‐based energy information, which is separated into two blocks (van der Waals and electrostatic), plus an additional column (<bold>Y</bold>
matrix) containing the experimental binding affinities. This <bold>X</bold>
matrix was then projected onto a small number of orthogonal LVs using partial least‐squares (PLS) analysis, and the original energy terms were given weights, <italic>w</italic>
<sub>i</sub>
, according to their importance in the model, in the form of PLS pseudo coefficients. The higher these coefficients are, the more significant they are for explaining the variance in the experimental data. Thus, in this study, the van der Waals interactions,
<mml:math id="nlm-math-1"><mml:msubsup><mml:mrow><mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow><mml:mi mathvariant="normal">i</mml:mi>
</mml:mrow>
<mml:mrow><mml:mtext>vdw</mml:mtext>
</mml:mrow>
</mml:msubsup>
</mml:math>
, and the electrostatic interactions,
<mml:math id="nlm-math-2"><mml:msubsup><mml:mrow><mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow><mml:mi mathvariant="normal">i</mml:mi>
</mml:mrow>
<mml:mrow><mml:mtext>ele</mml:mtext>
</mml:mrow>
</mml:msubsup>
</mml:math>
, between the inhibitor and each protein residue were selected to estimate the pIC<sub>50</sub>
value. The variables that were unimportant for activities were discarded, and the remaining variables were used to build the final PLS model. As a result of COMBINE analysis, gCOMBINE provided a summary of PLS weights, coefficients, rank, and files for PDB with coefficients. In the present study, the PLS ranks were calculated by 5.</p>
</sec>
</sec>
<sec id="bip22773-sec-0006"><title>RESULTS AND DISCUSSION</title>
<sec id="bip22773-sec-0007"><title>Design, Preparation, and Inhibitory Activities of Inhibitor 7 and 8</title>
<p>The compounds <bold>7</bold>
and <bold>8</bold>
were designed based on our previous structural analysis of 3CL<sup>pro</sup>
compounds, <bold>1</bold>
, <bold>2</bold>
, <bold>3</bold>
, <bold>4</bold>
, <bold>5</bold>
, and <bold>6</bold>
. Figure <xref rid="bip22773-fig-0001" ref-type="fig">1</xref>
shows a summary of our previous structural analysis of the complex with <bold>1</bold>
‐<bold>6</bold>
. The chemistry of the <italic>aza</italic>
‐decaline derived inhibitors including <bold>7</bold>
and <bold>8</bold>
was divided into three portions: histidine aldehyde (His‐al), <italic>aza</italic>
‐decaline, and an <italic>N</italic>
‐acyl part (Figure <xref rid="bip22773-fig-0001" ref-type="fig">1</xref>
B). The His‐al part took an almost identical conformation and similarly interacted with the 3CL<sup>pro</sup>
over the complexes examined. Briefly, His‐al is located at the active center of 3CL<sup>pro</sup>
as aldehyde and an imidazole ring interacted with the catalytic dyad, thiol of Cys, and imidazole of His, respectively. Thus, the His‐al part functioned as a pharmacophore in these compounds. In contrast, the <italic>N</italic>
‐acyl part of the <italic>aza</italic>
‐decaline based inhibitors, <bold>4</bold>
, <bold>5</bold>
, and <bold>6</bold>
were directed outward of 3CL<sup>pro</sup>
and then opposite to the P<sub>3</sub>
to P<sub>4</sub>
sites of peptide mimic inhibitors, <bold>1</bold>
, <bold>2</bold>
, and <bold>3</bold>
. Based on these observations, compounds <bold>7</bold>
and <bold>8</bold>
were designed as making an aromatic ring of the <italic>N</italic>
‐acyl part feasible to access the S<sub>3</sub>
or S<sub>4</sub>
pocket of 3CL<sup>pro</sup>
via a relatively flexible β‐alanine linker and are expected to provide greater potency. The stereochemistry of compounds <bold>7</bold>
and <bold>8</bold>
corresponded to compounds <bold>4</bold>
and <bold>5</bold>
, respectively.</p>
<p>As for the template for the synthesis of the designed compounds, <italic>aza</italic>
‐decaline is an attractive scaffold which is restricted in configuration and can provide distinct and relative positions and directions with substituents. Considering this ability of extension, among the three parts of the basic inhibitor design, an <italic>aza</italic>
‐decaline was constructed by two cyclization steps utilizing different chemistries, Diels‐Alder and diastereo‐selective cyclization by PdCl<sub>2</sub>
(AcCN)<sub>2</sub>
for cyclohexyl and <italic>aza</italic>
‐cyclohexyl on the cyclohexyl, respectively. Since the second cyclization is feasible to react with a wide variety of substrates, the acylation is scheduled in the early steps. On the other hand, since the His‐al part contains a labile group, aldehyde, the reductive amination is scheduled in the late steps. In the present study, the synthetic scheme worked well at least for synthesis of inhibitors <bold>4</bold>
‐<bold>8</bold>
. Production of a wide variety of inhibitors containing various stereochemistries is to be examined elsewhere based on these key reactions.<xref rid="bip22773-bib-0042" ref-type="ref">42</xref>
, <xref rid="bip22773-bib-0059" ref-type="ref">59</xref>
, <xref rid="bip22773-bib-0060" ref-type="ref">60</xref>
</p>
<p>Although compounds <bold>7</bold>
and <bold>8</bold>
were designed based on the structural analysis mentioned earlier, the IC<sub>50</sub>
s were not improved in comparison with those of the corresponding compounds <bold>4</bold>
and <bold>5</bold>
, respectively. Compound <bold>7</bold>
and <bold>8</bold>
inhibited hydrolysis of SARS 3CL<sup>pro</sup>
in IC<sub>50</sub>
, 275 μM and 215 μM, respectively.</p>
</sec>
<sec id="bip22773-sec-0008"><title>Structural Analysis of R188I SARS 3CL Protease Complexed with Compounds 7 and 8</title>
<p>To investigate the reasons for the deterioration in IC<sub>50</sub>
, crystallographic analyses of the SARS 3CL<sup>pro</sup>
in complexes with compounds <bold>7</bold>
and <bold>8</bold>
were performed. Data collection and refinement statistics for the R188I SARS 3CL protease with compounds <bold>7</bold>
and <bold>8</bold>
are summarized in Table <xref rid="bip22773-tbl-0002" ref-type="table">2</xref>
.</p>
<p>The overall structure of 3CL<sup>pro</sup>
in complex with inhibitors <bold>7</bold>
and <bold>8</bold>
was similar to the other <italic>aza</italic>
‐decaline‐based inhibitors (Figure <xref rid="bip22773-fig-0002" ref-type="fig">2</xref>
A). Briefly, the aldehyde group and imidazole ring of His‐al of these inhibitors took an almost identical conformation and similarly interacted with 3CL<sup>pro</sup>
. In contrast, the direction of the <italic>aza</italic>
‐substituents of the <italic>aza</italic>
‐decaline based inhibitors, <bold>7</bold>
and <bold>8</bold>
(Figure <xref rid="bip22773-fig-0002" ref-type="fig">2</xref>
B), were outward from 3CL<sup>pro</sup>
and opposite to the P<sub>3</sub>
to P<sub>4</sub>
sites of peptide mimic inhibitors <bold>1</bold>
, <bold>2</bold>
, and <bold>3</bold>
as in our previous inhibitors, <bold>4</bold>
, <bold>5</bold>
, and <bold>6</bold>
(Figure <xref rid="bip22773-fig-0001" ref-type="fig">1</xref>
A). Thus, crystallographic analyses of the SARS 3CL<sup>pro</sup>
in complexes with compounds <bold>7</bold>
and <bold>8</bold>
revealed that in our case the bAla was not functioning as a flexible linker to reach the Ph group of the hydrophobic S<sub>3</sub>
pocket. These features were in good accordance with the deteriorated IC<sub>50</sub>
s of <bold>7</bold>
and <bold>8</bold>
, which may be due to a higher entropic discordance of <bold>7</bold>
and <bold>8</bold>
than of <bold>4</bold>
and <bold>5</bold>
, respectively.</p>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0002" orientation="portrait" position="float"><label>Figure 2</label>
<caption><p>(A) Interactions of <bold>7</bold>
(PDB code 5C5O, left panel) and <bold>8</bold>
(PDB code 5C5N, right panel) at the active center of 3CL<sup>pro</sup>
. Red and blue meshes represent observed electron density corresponding to 3CL<sup>pro</sup>
and inhibitors, respectively. The inhibitors are shown in the stick model. The S<sub>2</sub>
pocket is located at the top, and the S<sub>1</sub>
pocket at the bottom interact with the <italic>aza</italic>
‐decaline and His‐al part of the inhibitor, respectively. (B) The <italic>N</italic>
‐acyl‐parts of <italic>aza</italic>
‐decaline‐based inhibitors <bold>7</bold>
and <bold>8</bold>
are directed outward from 3CL<sup>pro</sup>
. This figure is the same compositional arrangement as that of Figure 1(A).</p>
</caption>
<graphic id="nlm-graphic-19" xlink:href="BIP-106-391-g002"></graphic>
</fig>
<p>The <italic>trans aza</italic>
‐decaline scaffolds of <bold>7</bold>
and <bold>8</bold>
were adapted in the S<sub>2</sub>
pocket as deep as <bold>4</bold>
and <bold>5</bold>
, respectively. Based on these structural analyses focusing on the chemical structure of the inhibitors, several points to increase potency were revealed. The <italic>aza</italic>
‐decaline structure is sufficient to be adapted in the S<sub>2</sub>
pocket, and stereochemistry on the <italic>aza</italic>
‐decaline is a determinant for orientation in the S<sub>2</sub>
pocket (Figure <xref rid="bip22773-fig-0003" ref-type="fig">3</xref>
). Interestingly, the orientation of <italic>aza</italic>
‐decaline in the S<sub>2</sub>
pocket was not critical but was a determinant for relative potency; <bold>4</bold>
and <bold>7</bold>
were better than <bold>5</bold>
and <bold>8</bold>
, respectively, in which these scaffolds almost crossed perpendicular to each other when complex structures were superimposed by the whole protein. Thus, the <italic>trans aza</italic>
‐decaline scaffold is suitable for embedding into the S<sub>2</sub>
pocket. In comparison with peptide aldehyde inhibitors (Figure <xref rid="bip22773-fig-0004" ref-type="fig">4</xref>
), to make the <italic>N</italic>
‐acyl‐group of <italic>aza</italic>
‐decaline based inhibitors feasible to interact with the S<sub>3</sub>
and S<sub>4</sub>
sites, regioisomers such as 3, 3‐disubstituent or 3, 4‐subtituted <italic>trans aza</italic>
‐decaline may be necessary.</p>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0003" orientation="portrait" position="float"><label>Figure 3</label>
<caption><p>Comparison of the interaction mode of (3<italic>S</italic>
,4a<italic>R</italic>
,8a<italic>S</italic>
)‐ and (3<italic>R</italic>
,4a<italic>S</italic>
,8a<italic>R</italic>
)‐types. The <italic>aza</italic>
‐decaline part (3<italic>S</italic>
,4a<italic>R</italic>
,8a<italic>S</italic>
)‐type includes <bold>5</bold>
, <bold>6</bold>
, and <bold>7</bold>
(A) and (3<italic>R</italic>
,4a<italic>S</italic>
,8a<italic>R</italic>
)‐types include <bold>4</bold>
and <bold>8</bold>
(B). The left and right panels are in the same compositional arrangement in related 3CL<sup>pro</sup>
and are represented as a surface model.</p>
</caption>
<graphic id="nlm-graphic-21" xlink:href="BIP-106-391-g003"></graphic>
</fig>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0004" orientation="portrait" position="float"><label>Figure 4</label>
<caption><p>Comparison of directions of the P<sub>3</sub>
and P<sub>4</sub>
regions of peptide aldehyde inhibitors (A) and the <italic>N</italic>
‐acyl‐part of <italic>aza</italic>
‐decaline‐based inhibitors (B).</p>
</caption>
<graphic id="nlm-graphic-23" xlink:href="BIP-106-391-g004"></graphic>
</fig>
<p>Paasche et al.<xref rid="bip22773-bib-0061" ref-type="ref">61</xref>
have pointed out that the low inhibition potencies of known covalently interacting inhibitors may, at least in part, be attributed to insufficient fostering of the proton‐transfer reaction based on MM/MQ analysis of SARS 3CL<sup>pro</sup>
. Unfortunately, our method of study was incapable of accessing this charge state. Cleary and colleagues<xref rid="bip22773-bib-0062" ref-type="ref">62</xref>
showed that acetal or hemiacetal formation can be one of the components of the inhibitory potency for chymotrypsin. Among the eight complexes used in this study, structural refinements resulted in distances between the carbonyl carbon and sulfide ranging within 1.70–2.54 Å, which included distances judged as chemical bond formation by modeling software. There was, however, no correlation between this distance and potency (<italic>r</italic>
= −0.16).</p>
</sec>
<sec id="bip22773-sec-0009"><title>Quantitative Structure–Activity Relationship of R188I SARS 3CL Pro and Inhibitors</title>
<p>To investigate the structural basis of SARS 3CL<sup>pro</sup>
based on our results, a chemometrical analysis was applied to the crystallographic structures of the complex with inhibitors <bold>1</bold>
‐<bold>8</bold>
. The ligands, including peptide aldehyde, <bold>1</bold>
, <bold>2</bold>
, and <bold>3</bold>
, which are large enough to cover nonprime sites from P<sub>1</sub>
to P<sub>5</sub>
and two pairs of diasteroisomers of <italic>trans aza</italic>
‐decaline <bold>4</bold>
and <bold>7</bold>
and <bold>5</bold>
and <bold>8</bold>
, respectively, were expected to give fine structural diversity around the active site. The inputs for the COMBINE program are structural data including topology files, coordination files, and pharmacological activity correlated with ligand binding. In this study, the IC<sub>50</sub>
values were converted to negative logarithmic values, pIC<sub>50</sub>
s, which correlated with the binding free energy<xref rid="bip22773-bib-0063" ref-type="ref">63</xref>
, <xref rid="bip22773-bib-0064" ref-type="ref">64</xref>
of the inhibitors. In Table <xref rid="bip22773-tbl-0001" ref-type="table">1</xref>
, values ranging from 3.56 ‐ 7.19 are listed with the inhibitor and the ligand chemical structure.</p>
<p>Based on the input static structures, the program computes residue‐based van der Waals and electrostatic interactions between the residues in each complex and ligand for each complex (Figure <xref rid="bip22773-fig-0005" ref-type="fig">5</xref>
). Ligand‐binding pockets from S<sub>1</sub>
to S<sub>4</sub>
were clearly detected. Some of the pockets were located over the structural domains. The figure revealed that S<sub>1</sub>
and S<sub>2</sub>
contribute to inhibitor binding more than other pockets. Extensively, even in the region of S<sub>1</sub>
, in which all the examined inhibitors interacted with an identical His aldehyde structure, the calculated energies were not identical. This result illustrates that substitutions can affect fine interactions of the pharmacophore. These energy descriptors for each complex and the corresponding pIC<sub>50</sub>
comprise the <bold>X</bold>
and <bold>Y</bold>
matrix for the gCOMBINE analysis, respectively. The COMBINE program does PLS analysis such that the composed <bold>X</bold>
matrix is then projected onto a small number of orthogonal LVs in an optimized manner for protein–ligand interaction.</p>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0005" orientation="portrait" position="float"><label>Figure 5</label>
<caption><p>Interactions of 3CL<sup>pro</sup>
and the inhibitor in each complex by residual resolution. Vertical and horizontal axes represent the computed energy of van der Waals (upper graph) and electrostatic (lower graph) interactions and the residue number of 3CL<sup>pro</sup>
, respectively. At the top, the schematic drawing of the secondary structure of 3CL<sup>pro</sup>
along with the residue number is presented.</p>
</caption>
<graphic id="nlm-graphic-25" xlink:href="BIP-106-391-g005"></graphic>
</fig>
<p>Table <xref rid="bip22773-tbl-0003" ref-type="table">3</xref>
shows a chemometric summary of the analysis for the indices of 5 LVs. The optimal dimensionality of the PLS models was determined by monitoring the cross‐validation indexes as a function of the number of LVs extracted. The cross‐validation procedure employed the lease‐one‐out method. The predictive ability of the resulting models was reported by both the cross‐validated correlation coefficient (<italic>q</italic>
<sup>2</sup>
) and the standard deviation of error in the predictions. The <italic>q</italic>
<sup>2</sup>
value served as the criterion to determine the optimal dimensionality of the PLS model. Thus, for further analysis, we decided to take ranks by 2 as our model. At this rank, the linear regression analysis reached <italic>r</italic>
<sup>2</sup>
= 0.97 (correlation coefficient). Similar to the primary component analysis, this indicates that the first and second LVs contribute 87% and 10% of the explanation of pIC<sub>50</sub>
s in this system, respectively. These results indicate that the first two LVs can explain the pIC<sub>50</sub>
s of complexes to a considerable extent.</p>
<table-wrap id="bip22773-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label>
<caption><p>Extracted Statistical Summary of Chemometrical Analysis of 3CL<sup>pro</sup>
Complexes</p>
</caption>
<table frame="hsides" rules="groups"><col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<col style="border-bottom:solid 1px #000000; border-right:solid 1px #000000" span="1"></col>
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Numbers of LVs</th>
<th align="center" valign="bottom" rowspan="1" colspan="1"><italic>r</italic>
<sup>2</sup>
</th>
<th align="center" valign="bottom" rowspan="1" colspan="1"><italic>q</italic>
<sup>2</sup>
</th>
</tr>
</thead>
<tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">0.863</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">0.602</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>2</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><bold>0.971</bold>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"><bold>0.632</bold>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">3</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">0.993</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">0.577</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">4</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">1.000</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">0.570</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">5</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">1.000</td>
<td align="char" char="." valign="top" rowspan="1" colspan="1">0.571</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The COMBINE program gave several files corresponding to each rank of LV. In fact, for each complex, predicted pIC<sub>50</sub>
by the first two LVs and experimental pIC<sub>50</sub>
were in good correlation and clearly correlated with the corresponding experimental pIC<sub>50</sub>
as shown in Figure <xref rid="bip22773-fig-0006" ref-type="fig">6</xref>
. As a consequence, these 8 complexes composed a wide range of pIC<sub>50</sub>
s in the order of 3.5.</p>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0006" orientation="portrait" position="float"><label>Figure 6</label>
<caption><p>Scatter plot comparing experimental vs. predicted activities in COMBINE models for the eight complexes. The two LV model is represented. The straight line is (the diagonal) included in this plot as reference.</p>
</caption>
<graphic id="nlm-graphic-27" xlink:href="BIP-106-391-g006"></graphic>
</fig>
<p><bold>P</bold>
matrix (<bold>X</bold>
‐loading) in PLS to each LV reflects which and how much residue in a protein is contributing. Figure <xref rid="bip22773-fig-0007" ref-type="fig">7</xref>
shows a scatter plot of the part of the residues composing the first and second LVs in the horizontal and vertical axes, respectively. Among these elements which reflect the features of the first two LVs, the top 6 contributing residues for interaction were Pro<sup>168</sup>
, Glu<sup>166</sup>
, Met<sup>165</sup>
, Leu<sup>167</sup>
, Tyr<sup>161</sup>
, and Gln<sup>192</sup>
. On the other hand, Met<sup>49</sup>
prominently contributed a large portion of the second LV.</p>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0007" orientation="portrait" position="float"><label>Figure 7</label>
<caption><p>Scatter plot of amino acid residues contributing to the LVs. The vertical and horizontal axes correspond to the first and second LVs, respectively. The relevant energy descriptors have been labeled.</p>
</caption>
<graphic id="nlm-graphic-29" xlink:href="BIP-106-391-g007"></graphic>
</fig>
<p>For the first LV, residues mainly composing the S<sub>1</sub>
pocket and residues covering a wide range of binding sites were extracted. Thus, the first LV can be interpreted as it stands. Briefly, the first LV for inhibition reflects the fact that the pharmacophore interacts with active site fastening, and parts other than the pharmacophore interact with a wide range of binding sites as seen with peptide mimic inhibitors.</p>
<p>Next, the S<sub>2</sub>
pocket was highlighted in the examining residues related with the second LV. Among these residues, it was revealed that configuration of the dominant Met<sup>49</sup>
is connected to the inhibitory effect of ligand binding. Figure <xref rid="bip22773-fig-0008" ref-type="fig">8</xref>
A shows that the active site superimposed on the total 3CL<sup>pro</sup>
structures <bold>1</bold>
‐<bold>9</bold>
. Structure <bold>9</bold>
contains no inhibitor. The catalytic Cys‐His dyads were well overlapped. On the other hand, the configuration of Met<sup>49</sup>
side chains was separated into two groups. In one group, no ligand (<bold>9</bold>
), Leu side chain (<bold>1</bold>
), and (3<italic>R</italic>
,4a<italic>S</italic>
,8a<italic>R</italic>
) <italic>aza</italic>
‐decaline (<bold>4</bold>
and <bold>8</bold>
) were involved. In the other group, the Cha side chain (<bold>2</bold>
and <bold>3</bold>
) and (3<italic>S</italic>
,4a<italic>R</italic>
,8a<italic>S</italic>
) <italic>aza</italic>
‐decaline (<bold>5</bold>
, <bold>6</bold>
and <bold>7</bold>
) were involved. Inhibitors in the latter group had greater potency in comparison with the corresponding chemical structures. Thus, the S<sub>2</sub>
pocket is enlarged on the potent inhibitors by reorientation of the Met<sup>49</sup>
side chain. Figure <xref rid="bip22773-fig-0008" ref-type="fig">8</xref>
B shows the correlation between the <bold>X</bold>
score of each complex corresponding to the second LV model and each RMSD of the Met<sup>49</sup>
side chain heavy atom of complexes from that of structure <bold>9</bold>
. These values were strongly correlated with <italic>r</italic>
= 0.77. Thus, the main contribution to the second LV was the orientation of the Met<sup>49</sup>
side chain followed by enlarging the S<sub>2</sub>
pocket. The isobutyl group of the Leu side chain was not sufficient for inducing this reorientation. Even if a large functional group such as <italic>aza</italic>
‐decaline occupied the S<sub>2</sub>
pocket, the angle between the plane consisting of the chair‐chair configuration of <italic>aza</italic>
‐decaline and to Met<sup>49</sup>
was critical for the configurational change, which can be controlled by the stereochemistry of position 3 of the <italic>aza</italic>
‐decaline scaffold. These analyses revealed that the <italic>aza</italic>
‐decaline scaffold with stereochemistry of <italic>S</italic>
at position 3 is a novel scaffold for designing an inhibitor to 3CL<sup>pro</sup>
. As mentioned in inhibitor‐based analysis, optimized regioisomers need to be elucidated. The key feature of the interaction in the S<sub>2</sub>
pocket gives a novel strategy for developing a new inhibitor.</p>
<fig fig-type="Figure" xml:lang="en" id="bip22773-fig-0008" orientation="portrait" position="float"><label>Figure 8</label>
<caption><p>(A) Relative occupation and orientation of the catalytic dyad and Met<sup>49</sup>
side chains. Structure of 3CL<sup>pro</sup>
complexes with <bold>1</bold>
‐<bold>8</bold>
and <bold>9</bold>
were superimposed with the whole protein region. The side chains of the three residues are shown in the stick model. (B) Scatter plot showing the correlation between the second LV and orientation of the Met<sup>49</sup>
side chain. The vertical and horizontal axes correspond to the RMSD of Met<sup>49</sup>
from that of structure <bold>9</bold>
and the <bold>X</bold>
score of LV 2 for each complex.</p>
</caption>
<graphic id="nlm-graphic-31" xlink:href="BIP-106-391-g008"></graphic>
</fig>
<p>It is an important and unique strategy in COMBINE that multiple structures are involved in the analysis. This COMBINE strategy may, at least in part, represent the flexibility<xref rid="bip22773-bib-0065" ref-type="ref">65</xref>
, <xref rid="bip22773-bib-0066" ref-type="ref">66</xref>
, <xref rid="bip22773-bib-0067" ref-type="ref">67</xref>
of the protein upon ligand binding. In this research, not protein dynamic structural changes, but configurational change of side chains by inhibitor binding and their substantial control of inhibitory potency were detected. This fact highlights the advantages of the COMBINE method. Together with ligand‐based analysis and the COMIBINE analysis focusing on protein structure, a peptide mimetic inhibitor and development of a small molecular weight molecule is feasible. These sets of training on COMBINE will be adapted to modeled complexes such as docking simulations.</p>
<p>In conclusion, peptidic protease inhibitors were able to increase potency when designed based on structural analysis at each designing step. For <italic>aza</italic>
‐decaline based inhibitors, the potencies decreased during design. Structural analysis revealed that orientation of the substituent on the <italic>aza</italic>
‐decaline scaffold was not suitable for interacting with the protein. The COMBINE analysis revealed that the volume of the S<sub>2</sub>
pocket perturbed by stereochemistry of the ligand is important for inhibitor potency. This is derived as the second LV (10% explanation of the <bold>X</bold>
matrix). Further design and synthesis of inhibitors are expected.</p>
</sec>
<sec id="bip22773-sec-0010"><title>PDB ID Codes of Entry for This Article</title>
<p>5C5O and 5C5N</p>
<fig fig-type="Scheme" xml:lang="en" id="bip22773-fig-0009" orientation="portrait" position="float"><label>Scheme 1</label>
<caption><p>Synthesis of inhibitors 7 and 8. Abbreviations: DEAD: diethyl azodicarboxylate, DIBALH: diisobutylaluminum hydride, DIPEA: diisopropylethylamine, HBTU: <italic>O</italic>
‐(benzotriazol‐1‐yl)‐<italic>N,N,N′,N′</italic>
‐tetramethyluronium hexafluorophosphate, LAH: lithium aluminum hydride, PPh<sub>3</sub>
: triphenylphosphine, TFA: trifluoroacetic acid.</p>
</caption>
<graphic id="nlm-graphic-33" xlink:href="BIP-106-391-g009"></graphic>
</fig>
</sec>
</sec>
<sec id="bip22773-sec-0011"><p>The authors thank Ms. C. Teruya of Kyoto Pharmaceutical University for obtaining EI Mass spectra.</p>
</sec>
</body>
<back><ref-list content-type="cited-references"><title>REFERENCES</title>
<ref id="bip22773-bib-0001"><label>1</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0001"><string-name><surname>Lee</surname>
, <given-names>N.</given-names>
</string-name>
;
<string-name><surname>Hui</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>Wu</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Chan</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Cameron</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Joynt</surname>
, <given-names>G. M.</given-names>
</string-name>
;
<string-name><surname>Ahuja</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Yung</surname>
, <given-names>M. Y.</given-names>
</string-name>
;
<string-name><surname>Leung</surname>
, <given-names>C. B.</given-names>
</string-name>
;
<string-name><surname>To</surname>
, <given-names>K. F.</given-names>
</string-name>
;
<string-name><surname>Lui</surname>
, <given-names>S. F.</given-names>
</string-name>
;
<string-name><surname>Szeto</surname>
, <given-names>C. C.</given-names>
</string-name>
;
<string-name><surname>Chung</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Sung</surname>
, <given-names>J. J. Y.</given-names>
</string-name>
<source xml:lang="en">New Engl J Med</source>
<year>2003</year>
, <volume>348</volume>
, <fpage>1986</fpage>
–<lpage>1994</lpage>
.
<pub-id pub-id-type="pmid">12682352</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0002"><label>2</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0002"><string-name><surname>Drosten</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Günther</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Preiser</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>van der Werf</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Brodt</surname>
, <given-names>H. R.</given-names>
</string-name>
;
<string-name><surname>Becker</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Rabenau</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Panning</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Kolesnikova</surname>
, <given-names>L.</given-names>
</string-name>
;
<string-name><surname>Fouchier</surname>
, <given-names>R. A. M.</given-names>
</string-name>
;
<string-name><surname>Berger</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Burguière</surname>
, <given-names>A. M.</given-names>
</string-name>
;
<string-name><surname>Cinatl</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Eickmann</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Escriou</surname>
, <given-names>N.</given-names>
</string-name>
;
<string-name><surname>Grywna</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Kramme</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Manuguerra</surname>
, <given-names>J. C.</given-names>
</string-name>
;
<string-name><surname>Müller</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Rickerts</surname>
, <given-names>V.</given-names>
</string-name>
;
<string-name><surname>Stürmer</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Vieth</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Klenk</surname>
, <given-names>H. D.</given-names>
</string-name>
;
<string-name><surname>Osterhaus</surname>
, <given-names>A. D. M. E.</given-names>
</string-name>
;
<string-name><surname>Schmitz</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Doerr</surname>
, <given-names>H. W.</given-names>
</string-name>
<source xml:lang="en">New Engl J Med</source>
<year>2003</year>
, <volume>348</volume>
, <fpage>1967</fpage>
–<lpage>1976</lpage>
.
<pub-id pub-id-type="pmid">12690091</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0003"><label>3</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0003"><string-name><surname>Ksiazek</surname>
, <given-names>T. G.</given-names>
</string-name>
;
<string-name><surname>Erdman</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>Goldsmith</surname>
, <given-names>C. S.</given-names>
</string-name>
;
<string-name><surname>Zaki</surname>
, <given-names>S. R.</given-names>
</string-name>
;
<string-name><surname>Peret</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Emery</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Tong</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Urbani</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Comer</surname>
, <given-names>J. A.</given-names>
</string-name>
;
<string-name><surname>Lim</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Rollin</surname>
, <given-names>P. E.</given-names>
</string-name>
;
<string-name><surname>Dowell</surname>
, <given-names>S. F.</given-names>
</string-name>
;
<string-name><surname>Ling</surname>
, <given-names>A. E.</given-names>
</string-name>
;
<string-name><surname>Humphrey</surname>
, <given-names>C. D.</given-names>
</string-name>
;
<string-name><surname>Shieh</surname>
, <given-names>W. J.</given-names>
</string-name>
;
<string-name><surname>Guarner</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Paddock</surname>
, <given-names>C. D.</given-names>
</string-name>
;
<string-name><surname>Rota</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Fields</surname>
, <given-names>B.</given-names>
</string-name>
;
<string-name><surname>DeRisi</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Yang</surname>
, <given-names>J. Y.</given-names>
</string-name>
;
<string-name><surname>Cox</surname>
, <given-names>N.</given-names>
</string-name>
;
<string-name><surname>Hughes</surname>
, <given-names>J. M.</given-names>
</string-name>
;
<string-name><surname>LeDuc</surname>
, <given-names>J. W.</given-names>
</string-name>
;
<string-name><surname>Bellini</surname>
, <given-names>W. J.</given-names>
</string-name>
;
<string-name><surname>Anderson</surname>
, <given-names>L.</given-names>
</string-name>
<source xml:lang="en">J New Engl J Med</source>
<year>2003</year>
, <volume>348</volume>
, <fpage>1953</fpage>
–<lpage>1966</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0004"><label>4</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0004"><string-name><surname>Li</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Shi</surname>
, <given-names>Z.</given-names>
</string-name>
;
<string-name><surname>Yu</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Ren</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Smith</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Epstein</surname>
, <given-names>J. H.</given-names>
</string-name>
;
<string-name><surname>Wang</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Crameri</surname>
, <given-names>G.</given-names>
</string-name>
;
<string-name><surname>Hu</surname>
, <given-names>Z.</given-names>
</string-name>
;
<string-name><surname>Zhang</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Zhang</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>McEachern</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Field</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Daszak</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Eaton</surname>
, <given-names>B. T.</given-names>
</string-name>
;
<string-name><surname>Zhang</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Wang</surname>
, <given-names>L. F.</given-names>
</string-name>
<source xml:lang="en">Science</source>
<year>2005</year>
, <volume>310</volume>
, <fpage>676</fpage>
–<lpage>679</lpage>
.
<pub-id pub-id-type="pmid">16195424</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0005"><label>5</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0005"><string-name><surname>Lau</surname>
, <given-names>S. K. P.</given-names>
</string-name>
;
<string-name><surname>Woo</surname>
, <given-names>P. C. Y.</given-names>
</string-name>
;
<string-name><surname>Li</surname>
, <given-names>K. S. M.</given-names>
</string-name>
;
<string-name><surname>Huang</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Tsoi</surname>
, <given-names>H. W.</given-names>
</string-name>
;
<string-name><surname>Wong</surname>
, <given-names>B. H. L.</given-names>
</string-name>
;
<string-name><surname>Wong</surname>
, <given-names>S. S. Y.</given-names>
</string-name>
;
<string-name><surname>Leung</surname>
, <given-names>S. Y.</given-names>
</string-name>
;
<string-name><surname>Chan</surname>
, <given-names>K. H.</given-names>
</string-name>
;
<string-name><surname>Yuen</surname>
, <given-names>K. Y. P.</given-names>
</string-name>
<source xml:lang="en">Proc Natl Acad Sci USA</source>
<year>2005</year>
, <volume>102</volume>
, <fpage>14040</fpage>
–<lpage>14045</lpage>
.
<pub-id pub-id-type="pmid">16169905</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0006"><label>6</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0006"><string-name><surname>Anand</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Ziebuhr</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Wadhwani</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Mesters</surname>
, <given-names>J. R.</given-names>
</string-name>
;
<string-name><surname>Hilgenfeld</surname>
, <given-names>R.</given-names>
</string-name>
<source xml:lang="en">Science</source>
<year>2003</year>
, <volume>300</volume>
, <fpage>1763</fpage>
–<lpage>1767</lpage>
.
<pub-id pub-id-type="pmid">12746549</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0007"><label>7</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0007"><string-name><surname>Fan</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Wei</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Feng</surname>
, <given-names>Q.</given-names>
</string-name>
;
<string-name><surname>Chen</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Huang</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Ma</surname>
, <given-names>L.</given-names>
</string-name>
;
<string-name><surname>Lai</surname>
, <given-names>B.</given-names>
</string-name>
;
<string-name><surname>Pei</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Liu</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Chen</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Lai</surname>
, <given-names>L.</given-names>
</string-name>
<source xml:lang="en">J Biol Chem</source>
<year>2004</year>
, <volume>279</volume>
, <fpage>1637</fpage>
–<lpage>1642</lpage>
.
<pub-id pub-id-type="pmid">14561748</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0008"><label>8</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0008"><string-name><surname>Akaji</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Konno</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Mitsui</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Teruya</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Shimamoto</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Hattori</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Ozaki</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Kusunoki</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Sanjoh</surname>
, <given-names>A.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2011</year>
, <volume>54</volume>
, <fpage>7962</fpage>
–<lpage>7973</lpage>
.
<pub-id pub-id-type="pmid">22014094</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0009"><label>9</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0009"><string-name><surname>Thanigaimalai</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Konno</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Yamamoto</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Koiwai</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Taguchi</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Takayama</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Yakushiji</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Akaji</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Kiso</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Kawasaki</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Chen</surname>
, <given-names>S. E.</given-names>
</string-name>
;
<string-name><surname>Naser‐Tavakolian</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Schön</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Freire</surname>
, <given-names>E.</given-names>
</string-name>
;
<string-name><surname>Hayashi</surname>
, <given-names>Y.</given-names>
</string-name>
<source xml:lang="en">Eur J Med Chem</source>
<year>2013</year>
, <volume>65</volume>
, <fpage>436</fpage>
–<lpage>447</lpage>
.
<pub-id pub-id-type="pmid">23747811</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0010"><label>10</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0010"><string-name><surname>Chuck</surname>
, <given-names>C. P.</given-names>
</string-name>
;
<string-name><surname>Chen</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Ke</surname>
, <given-names>Z.</given-names>
</string-name>
;
<string-name><surname>Chi‐Cheong Wan</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>Chow</surname>
, <given-names>H. F.</given-names>
</string-name>
;
<string-name><surname>Wong</surname>
, <given-names>K. B.</given-names>
</string-name>
<source xml:lang="en">Eur J Med Chem</source>
<year>2013</year>
, <volume>59</volume>
, <fpage>1</fpage>
–<lpage>6</lpage>
.
<pub-id pub-id-type="pmid">23202846</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0011"><label>11</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0011"><string-name><surname>Regnier</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Sarma</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>Hidaka</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Bacha</surname>
, <given-names>U.</given-names>
</string-name>
;
<string-name><surname>Freire</surname>
, <given-names>E.</given-names>
</string-name>
;
<string-name><surname>Hayashi</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Kiso</surname>
, <given-names>Y.</given-names>
</string-name>
<source xml:lang="en">Bioorg Med Chem Lett</source>
<year>2009</year>
, <volume>19</volume>
, <fpage>2722</fpage>
–<lpage>2727</lpage>
.
<pub-id pub-id-type="pmid">19362479</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0012"><label>12</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0012"><string-name><surname>Ghosh</surname>
, <given-names>A. K.</given-names>
</string-name>
;
<string-name><surname>Xi</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Grum‐Tokars</surname>
, <given-names>V.</given-names>
</string-name>
;
<string-name><surname>Xu</surname>
, <given-names>X.</given-names>
</string-name>
;
<string-name><surname>Ratia</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Fu</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Houser</surname>
, <given-names>K. V.</given-names>
</string-name>
;
<string-name><surname>Baker</surname>
, <given-names>S. C.</given-names>
</string-name>
;
<string-name><surname>Johnson</surname>
, <given-names>M. E.</given-names>
</string-name>
;
<string-name><surname>Mesecar</surname>
, <given-names>A. D.</given-names>
</string-name>
<source xml:lang="en">Bioorg Med Chem Lett</source>
<year>2007</year>
, <volume>17</volume>
, <fpage>5876</fpage>
–<lpage>5880</lpage>
.
<pub-id pub-id-type="pmid">17855091</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0013"><label>13</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0013"><string-name><surname>Park</surname>
, <given-names>J. Y.</given-names>
</string-name>
;
<string-name><surname>Kim</surname>
, <given-names>J. H.</given-names>
</string-name>
;
<string-name><surname>Kwon</surname>
, <given-names>J. M.</given-names>
</string-name>
;
<string-name><surname>Kwon</surname>
, <given-names>H. J.</given-names>
</string-name>
;
<string-name><surname>Jeong</surname>
, <given-names>H. J.</given-names>
</string-name>
;
<string-name><surname>Kim</surname>
, <given-names>Y. M.</given-names>
</string-name>
;
<string-name><surname>Kim</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>Lee</surname>
, <given-names>W. S.</given-names>
</string-name>
;
<string-name><surname>Ryu</surname>
, <given-names>Y. B.</given-names>
</string-name>
<source xml:lang="en">Bioorgan Med Chem</source>
<year>2013</year>
, <volume>21</volume>
, <fpage>3730</fpage>
–<lpage>3737</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0014"><label>14</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0014"><string-name><surname>Ryu</surname>
, <given-names>Y. B.</given-names>
</string-name>
;
<string-name><surname>Park</surname>
, <given-names>S. J.</given-names>
</string-name>
;
<string-name><surname>Kim</surname>
, <given-names>Y. M.</given-names>
</string-name>
;
<string-name><surname>Lee</surname>
, <given-names>J. Y.</given-names>
</string-name>
;
<string-name><surname>Seo</surname>
, <given-names>W. D.</given-names>
</string-name>
;
<string-name><surname>Chang</surname>
, <given-names>J. S.</given-names>
</string-name>
;
<string-name><surname>Park</surname>
, <given-names>K. H.</given-names>
</string-name>
;
<string-name><surname>Rho</surname>
, <given-names>M. C.</given-names>
</string-name>
;
<string-name><surname>Lee</surname>
, <given-names>W. S.</given-names>
</string-name>
<source xml:lang="en">Bioorg Med Chem Lett</source>
<year>2010</year>
, <volume>20</volume>
, <fpage>1873</fpage>
–<lpage>1876</lpage>
.
<pub-id pub-id-type="pmid">20167482</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0015"><label>15</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0015"><string-name><surname>Wen</surname>
, <given-names>C. C.</given-names>
</string-name>
;
<string-name><surname>Kuo</surname>
, <given-names>Y. H.</given-names>
</string-name>
;
<string-name><surname>Jan</surname>
, <given-names>J. T.</given-names>
</string-name>
;
<string-name><surname>Liang</surname>
, <given-names>P. H.</given-names>
</string-name>
;
<string-name><surname>Wang</surname>
, <given-names>S. Y.</given-names>
</string-name>
;
<string-name><surname>Liu</surname>
, <given-names>H. G.</given-names>
</string-name>
;
<string-name><surname>Lee</surname>
, <given-names>C. K.</given-names>
</string-name>
;
<string-name><surname>Chang</surname>
, <given-names>S. T.</given-names>
</string-name>
;
<string-name><surname>Kuo</surname>
, <given-names>C. J.</given-names>
</string-name>
;
<string-name><surname>Lee</surname>
, <given-names>S. S.</given-names>
</string-name>
;
<string-name><surname>Hou</surname>
, <given-names>C. C.</given-names>
</string-name>
;
<string-name><surname>Hsiao</surname>
, <given-names>P. W.</given-names>
</string-name>
;
<string-name><surname>Chien</surname>
, <given-names>S. C.</given-names>
</string-name>
;
<string-name><surname>Shyur</surname>
, <given-names>L. F.</given-names>
</string-name>
;
<string-name><surname>Yang</surname>
, <given-names>N. S.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2007</year>
, <volume>50</volume>
, <fpage>4087</fpage>
–<lpage>4095</lpage>
.
<pub-id pub-id-type="pmid">17663539</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0016"><label>16</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0016"><string-name><surname>Ikejiri</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Saijo</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Morikawa</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Fukushi</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Mizutani</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Kurane</surname>
, <given-names>I.</given-names>
</string-name>
;
<string-name><surname>Maruyama</surname>
, <given-names>T.</given-names>
</string-name>
<source xml:lang="en">Bioorg Med Chem Lett</source>
<year>2007</year>
, <volume>17</volume>
, <fpage>2470</fpage>
–<lpage>2473</lpage>
.
<pub-id pub-id-type="pmid">17336519</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0017"><label>17</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0017"><string-name><surname>Cho</surname>
, <given-names>J. H.</given-names>
</string-name>
;
<string-name><surname>Bernard</surname>
, <given-names>D. L.</given-names>
</string-name>
;
<string-name><surname>Sidwell</surname>
, <given-names>R. W.</given-names>
</string-name>
;
<string-name><surname>Kern</surname>
, <given-names>E. R.</given-names>
</string-name>
;
<string-name><surname>Chu</surname>
, <given-names>C. K.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2006</year>
, <volume>49</volume>
, <fpage>1140</fpage>
–<lpage>1148</lpage>
.
<pub-id pub-id-type="pmid">16451078</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0018"><label>18</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0018"><string-name><surname>Biot</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Daher</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Chavain</surname>
, <given-names>N.</given-names>
</string-name>
;
<string-name><surname>Fandeur</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Khalife</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Dive</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>De Clercq</surname>
, <given-names>E.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2006</year>
, <volume>49</volume>
, <fpage>2845</fpage>
–<lpage>2849</lpage>
.
<pub-id pub-id-type="pmid">16640347</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0019"><label>19</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0019"><string-name><surname>Liu</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Zhu</surname>
, <given-names>H. M.</given-names>
</string-name>
;
<string-name><surname>Niu</surname>
, <given-names>G. J.</given-names>
</string-name>
;
<string-name><surname>Shi</surname>
, <given-names>E. Z.</given-names>
</string-name>
;
<string-name><surname>Chen</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Sun</surname>
, <given-names>B.</given-names>
</string-name>
;
<string-name><surname>Chen</surname>
, <given-names>W. Q.</given-names>
</string-name>
;
<string-name><surname>Zhou</surname>
, <given-names>H. G.</given-names>
</string-name>
;
<string-name><surname>Yang</surname>
, <given-names>C.</given-names>
</string-name>
<source xml:lang="en">Bioorgan Med Chem</source>
<year>2014</year>
, <volume>22</volume>
, <fpage>292</fpage>
–<lpage>302</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0020"><label>20</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0020"><string-name><surname>Lee</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Mittal</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Patel</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Gatuz</surname>
, <given-names>J. L.</given-names>
</string-name>
;
<string-name><surname>Truong</surname>
, <given-names>L.</given-names>
</string-name>
;
<string-name><surname>Torres</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Mulhearn</surname>
, <given-names>D. C.</given-names>
</string-name>
;
<string-name><surname>Johnson</surname>
, <given-names>M. E.</given-names>
</string-name>
<source xml:lang="en">Bioorgan Med Chem</source>
<year>2014</year>
, <volume>22</volume>
, <fpage>167</fpage>
–<lpage>177</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0021"><label>21</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0021"><string-name><surname>Jacobs</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Grum‐Tokars</surname>
, <given-names>V.</given-names>
</string-name>
;
<string-name><surname>Zhou</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Turlington</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Saldanha</surname>
, <given-names>S. A.</given-names>
</string-name>
;
<string-name><surname>Chase</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Eggler</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Dawson</surname>
, <given-names>E. S.</given-names>
</string-name>
;
<string-name><surname>Baez‐Santos</surname>
, <given-names>Y. M.</given-names>
</string-name>
;
<string-name><surname>Tomar</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Mielech</surname>
, <given-names>A. M.</given-names>
</string-name>
;
<string-name><surname>Baker</surname>
, <given-names>S. C.</given-names>
</string-name>
;
<string-name><surname>Lindsley</surname>
, <given-names>C. W.</given-names>
</string-name>
;
<string-name><surname>Hodder</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Mesecar</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Stauffer</surname>
, <given-names>S. R.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2013</year>
, <volume>56</volume>
, <fpage>534</fpage>
–<lpage>546</lpage>
.
<pub-id pub-id-type="pmid">23231439</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0022"><label>22</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0022"><string-name><surname>Ramajayam</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Tan</surname>
, <given-names>K. P.</given-names>
</string-name>
;
<string-name><surname>Liu</surname>
, <given-names>H. G.</given-names>
</string-name>
;
<string-name><surname>Liang</surname>
, <given-names>P. H.</given-names>
</string-name>
<source xml:lang="en">Bioorgan Med Chem</source>
<year>2010</year>
, <volume>18</volume>
, <fpage>7849</fpage>
–<lpage>7854</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0023"><label>23</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0023"><string-name><surname>Akaji</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Konno</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Onozuka</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Makino</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Saito</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Nosaka</surname>
, <given-names>K.</given-names>
</string-name>
<source xml:lang="en">Bioorgan Med Chem</source>
<year>2008</year>
, <volume>16</volume>
, <fpage>9400</fpage>
–<lpage>9408</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0024"><label>24</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0024"><string-name><surname>Shimamoto</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Hattori</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Kobayashi</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Teruya</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Sanjoh</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Nakagawa</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Yamashita</surname>
, <given-names>E.</given-names>
</string-name>
;
<string-name><surname>Akaji</surname>
, <given-names>K.</given-names>
</string-name>
<source xml:lang="en">Bioorgan Med Chem</source>
<year>2015</year>
, <volume>23</volume>
, <fpage>876</fpage>
–<lpage>890</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0025"><label>25</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0025"><string-name><surname>Ortiz</surname>
, <given-names>A. R.</given-names>
</string-name>
;
<string-name><surname>Pisabarro</surname>
, <given-names>M. T.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Wade</surname>
, <given-names>R. C.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>1995</year>
, <volume>38</volume>
, <fpage>2681</fpage>
–<lpage>2691</lpage>
.
<pub-id pub-id-type="pmid">7629807</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0026"><label>26</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0026"><string-name><surname>Gil‐Redondo</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Klett</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Morreale</surname>
, <given-names>A.</given-names>
</string-name>
<source xml:lang="en">Proteins</source>
<year>2010</year>
, <volume>78</volume>
, <fpage>162</fpage>
–<lpage>172</lpage>
.
<pub-id pub-id-type="pmid">19705486</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0027"><label>27</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0027"><string-name><surname>Coderch</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Tang</surname>
, <given-names>Y.</given-names>
</string-name>
;
<string-name><surname>Klett</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Zhang</surname>
, <given-names>S. E.</given-names>
</string-name>
;
<string-name><surname>Ma</surname>
, <given-names>Y. T.</given-names>
</string-name>
;
<string-name><surname>Shaorong</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Matesanz</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Pera</surname>
, <given-names>B.</given-names>
</string-name>
;
<string-name><surname>Canales</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Jiménez‐Barbero</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Morreale</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Díaz</surname>
, <given-names>J. F.</given-names>
</string-name>
;
<string-name><surname>Fang</surname>
, <given-names>W. S.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
<source xml:lang="en">Org Biomol Chem</source>
<year>2013</year>
, <volume>11</volume>
, <fpage>3046</fpage>
<pub-id pub-id-type="pmid">23532250</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0028"><label>28</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0028"><string-name><surname>Coderch</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Klett</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Morreale</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Díaz</surname>
, <given-names>J. F.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
<source xml:lang="en">ChemMedChem</source>
<year>2012</year>
, <volume>7</volume>
, <fpage>836</fpage>
–<lpage>843</lpage>
.
<pub-id pub-id-type="pmid">22431398</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0029"><label>29</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0029"><string-name><surname>Guo</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Hurley</surname>
, <given-names>M. M.</given-names>
</string-name>
;
<string-name><surname>Wright</surname>
, <given-names>J. B.</given-names>
</string-name>
;
<string-name><surname>Lushington</surname>
, <given-names>G. H.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2004</year>
, <volume>47</volume>
, <fpage>5492</fpage>
–<lpage>5500</lpage>
.
<pub-id pub-id-type="pmid">15481986</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0030"><label>30</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0030"><string-name><surname>Kim</surname>
, <given-names>H. J.</given-names>
</string-name>
;
<string-name><surname>Chae</surname>
, <given-names>C. H.</given-names>
</string-name>
;
<string-name><surname>Yi</surname>
, <given-names>K. Y.</given-names>
</string-name>
;
<string-name><surname>Park</surname>
, <given-names>K. L.</given-names>
</string-name>
;
<string-name><surname>Yoo</surname>
, <given-names>S.</given-names>
</string-name>
<source xml:lang="en">Bioorg Med Chem</source>
<year>2004</year>
, <volume>12</volume>
, <fpage>1629</fpage>
–<lpage>1641</lpage>
.
<pub-id pub-id-type="pmid">15028256</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0031"><label>31</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0031"><string-name><surname>Liu</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Fu</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Cheng</surname>
, <given-names>X.</given-names>
</string-name>
;
<string-name><surname>Chen</surname>
, <given-names>S. P.</given-names>
</string-name>
;
<string-name><surname>Zhou</surname>
, <given-names>L. H.</given-names>
</string-name>
<source xml:lang="en">BMC Struct Biol</source>
<year>2012</year>
, <volume>12</volume>
, <fpage>21</fpage>
<pub-id pub-id-type="pmid">22925713</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0032"><label>32</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0032"><string-name><surname>Murcia</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Morreale</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Ortiz</surname>
, <given-names>A. R.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2006</year>
, <volume>49</volume>
, <fpage>6241</fpage>
–<lpage>6253</lpage>
.
<pub-id pub-id-type="pmid">17034130</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0033"><label>33</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0033"><string-name><surname>Nakamura</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Nakanishi</surname>
, <given-names>I.</given-names>
</string-name>
;
<string-name><surname>Kitaura</surname>
, <given-names>K.</given-names>
</string-name>
<source xml:lang="en">Bioorg Med Chem Lett</source>
<year>2006</year>
, <volume>16</volume>
, <fpage>6334</fpage>
–<lpage>6337</lpage>
.
<pub-id pub-id-type="pmid">17027266</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0034"><label>34</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0034"><string-name><surname>Ortiz</surname>
, <given-names>A. R.</given-names>
</string-name>
;
<string-name><surname>Pastor</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Palomer</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Cruciani</surname>
, <given-names>G.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Wade</surname>
, <given-names>R. C.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>1997</year>
, <volume>40</volume>
, <fpage>1136</fpage>
–<lpage>1148</lpage>
.
<pub-id pub-id-type="pmid">9089335</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0035"><label>35</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0035"><string-name><surname>Peón</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Coderch</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>González‐Bello</surname>
, <given-names>C.</given-names>
</string-name>
<source xml:lang="en">ChemMedChem</source>
<year>2013</year>
, <volume>8</volume>
, <fpage>740</fpage>
–<lpage>747</lpage>
.
<pub-id pub-id-type="pmid">23450741</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0036"><label>36</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0036"><string-name><surname>Pérez</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Pastor</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Ortiz</surname>
, <given-names>A. R.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>1998</year>
, <volume>41</volume>
, <fpage>836</fpage>
–<lpage>852</lpage>
.
<pub-id pub-id-type="pmid">9526559</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0037"><label>37</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0037"><string-name><surname>Rodríguez‐Barrios</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
<source xml:lang="en">J Am Chem Soc</source>
<year>2004</year>
, <volume>126</volume>
, <fpage>2718</fpage>
–<lpage>2719</lpage>
.
<pub-id pub-id-type="pmid">14995186</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0038"><label>38</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0038"><string-name><surname>Rotili</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>Samuele</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Tarantino</surname>
, <given-names>D.</given-names>
</string-name>
;
<string-name><surname>Ragno</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Musmuca</surname>
, <given-names>I.</given-names>
</string-name>
;
<string-name><surname>Ballante</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Botta</surname>
, <given-names>G.</given-names>
</string-name>
;
<string-name><surname>Morera</surname>
, <given-names>L.</given-names>
</string-name>
;
<string-name><surname>Pierini</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Cirilli</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Nawrozkij</surname>
, <given-names>M. B.</given-names>
</string-name>
;
<string-name><surname>Gonzalez</surname>
, <given-names>E.</given-names>
</string-name>
;
<string-name><surname>Clotet</surname>
, <given-names>B.</given-names>
</string-name>
;
<string-name><surname>Artico</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Esté</surname>
, <given-names>J. A.</given-names>
</string-name>
;
<string-name><surname>Maga</surname>
, <given-names>G.</given-names>
</string-name>
;
<string-name><surname>Mai</surname>
, <given-names>A.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2012</year>
, <volume>55</volume>
, <fpage>3558</fpage>
–<lpage>3562</lpage>
.
<pub-id pub-id-type="pmid">22428851</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0039"><label>39</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0039"><string-name><surname>Silvestri</surname>
, <given-names>L.</given-names>
</string-name>
;
<string-name><surname>Ballante</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Mai</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Marshall</surname>
, <given-names>G. R.</given-names>
</string-name>
;
<string-name><surname>Ragno</surname>
, <given-names>R.</given-names>
</string-name>
<source xml:lang="en">J Chem Inf Model</source>
<year>2012</year>
, <volume>52</volume>
, <fpage>2215</fpage>
–<lpage>2235</lpage>
.
<pub-id pub-id-type="pmid">22762501</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0040"><label>40</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0040"><string-name><surname>Wang</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Wade</surname>
, <given-names>R. C.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2001</year>
, <volume>44</volume>
, <fpage>961</fpage>
–<lpage>971</lpage>
.
<pub-id pub-id-type="pmid">11300878</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0041"><label>41</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0041"><string-name><surname>Wang</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Tomic</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Gabdoulline</surname>
, <given-names>R. R.</given-names>
</string-name>
;
<string-name><surname>Wade</surname>
, <given-names>R. C.</given-names>
</string-name>
<source xml:lang="en">Biophys J</source>
<year>2004</year>
, <volume>87</volume>
, <fpage>1618</fpage>
–<lpage>1630</lpage>
.
<pub-id pub-id-type="pmid">15345541</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0042"><label>42</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0042"><string-name><surname>Makabe</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Kong</surname>
, <given-names>L. K.</given-names>
</string-name>
;
<string-name><surname>Hirota</surname>
, <given-names>M.</given-names>
</string-name>
<source xml:lang="en">Org Lett</source>
<year>2003</year>
, <volume>5</volume>
, <fpage>27</fpage>
–<lpage>29</lpage>
.
<pub-id pub-id-type="pmid">12509882</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0043"><label>43</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0043"><string-name><surname>Vagin</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Teplyakov</surname>
, <given-names>A.</given-names>
</string-name>
<source xml:lang="en">Acta Crystallogr D</source>
<year>2010</year>
, <volume>66</volume>
, <fpage>22</fpage>
–<lpage>25</lpage>
.
<pub-id pub-id-type="pmid">20057045</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0044"><label>44</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0044"><string-name><surname>Murshudov</surname>
, <given-names>G. N.</given-names>
</string-name>
;
<string-name><surname>Vagin</surname>
, <given-names>A. A.</given-names>
</string-name>
;
<string-name><surname>Dodson</surname>
, <given-names>E.</given-names>
</string-name>
<source xml:lang="en">J Acta Crystallogr D</source>
<year>1997</year>
, <volume>53</volume>
, <fpage>240</fpage>
–<lpage>255</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0045"><label>45</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0045"><string-name><surname>Winn</surname>
, <given-names>M. D.</given-names>
</string-name>
;
<string-name><surname>Ballard</surname>
, <given-names>C. C.</given-names>
</string-name>
;
<string-name><surname>Cowtan</surname>
, <given-names>K. D.</given-names>
</string-name>
;
<string-name><surname>Dodson</surname>
, <given-names>E. J.</given-names>
</string-name>
;
<string-name><surname>Emsley</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Evans</surname>
, <given-names>P. R.</given-names>
</string-name>
;
<string-name><surname>Keegan</surname>
, <given-names>R. M.</given-names>
</string-name>
;
<string-name><surname>Krissinel</surname>
, <given-names>E. B.</given-names>
</string-name>
;
<string-name><surname>Leslie</surname>
, <given-names>A. G. W.</given-names>
</string-name>
;
<string-name><surname>McCoy</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>McNicholas</surname>
, <given-names>S. J.</given-names>
</string-name>
;
<string-name><surname>Murshudov</surname>
, <given-names>G. N.</given-names>
</string-name>
;
<string-name><surname>Pannu</surname>
, <given-names>N. S.</given-names>
</string-name>
;
<string-name><surname>Potterton</surname>
, <given-names>E. A.</given-names>
</string-name>
;
<string-name><surname>Powell</surname>
, <given-names>H. R.</given-names>
</string-name>
;
<string-name><surname>Read</surname>
, <given-names>R. J.</given-names>
</string-name>
;
<string-name><surname>Vagin</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Wilson</surname>
, <given-names>K. S.</given-names>
</string-name>
<source xml:lang="en">Acta Crystallogr D</source>
<year>2011</year>
, <volume>67</volume>
, <fpage>235</fpage>
–<lpage>242</lpage>
.
<pub-id pub-id-type="pmid">21460441</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0046"><label>46</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0046"><string-name><surname>Emsley</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Cowtan</surname>
, <given-names>K.</given-names>
</string-name>
<source xml:lang="en">Acta Crystallogr D</source>
<year>2004</year>
, <volume>60</volume>
, <fpage>2126</fpage>
–<lpage>2132</lpage>
.
<pub-id pub-id-type="pmid">15572765</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0047"><label>47</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0047"><string-name><surname>Lebedev</surname>
, <given-names>A. A.</given-names>
</string-name>
;
<string-name><surname>Young</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Isupov</surname>
, <given-names>M. N.</given-names>
</string-name>
;
<string-name><surname>Moroz</surname>
, <given-names>O. V.</given-names>
</string-name>
;
<string-name><surname>Vagin</surname>
, <given-names>A. A.</given-names>
</string-name>
;
<string-name><surname>Murshudov</surname>
, <given-names>G. N.</given-names>
</string-name>
<source xml:lang="en">Acta Crystallogr D</source>
<year>2012</year>
, <volume>68</volume>
, <fpage>431</fpage>
–<lpage>440</lpage>
.
<pub-id pub-id-type="pmid">22505263</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0048"><label>48</label>
<mixed-citation publication-type="miscellaneous" id="bip22773-cit-0048">The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC
</mixed-citation>
</ref>
<ref id="bip22773-bib-0049"><label>49</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0049"><string-name><surname>Pettersen</surname>
, <given-names>E. F.</given-names>
</string-name>
;
<string-name><surname>Goddard</surname>
, <given-names>T. D.</given-names>
</string-name>
;
<string-name><surname>Huang</surname>
, <given-names>C. C.</given-names>
</string-name>
;
<string-name><surname>Couch</surname>
, <given-names>G. S.</given-names>
</string-name>
;
<string-name><surname>Greenblatt</surname>
, <given-names>D. M.</given-names>
</string-name>
;
<string-name><surname>Meng</surname>
, <given-names>E. C.</given-names>
</string-name>
;
<string-name><surname>Ferrin</surname>
, <given-names>T. E.</given-names>
</string-name>
<source xml:lang="en">J Comput Chem</source>
<year>2004</year>
, <volume>25</volume>
, <fpage>1605</fpage>
–<lpage>1612</lpage>
.
<pub-id pub-id-type="pmid">15264254</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0050"><label>50</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0050"><string-name><surname>Berman</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Henrick</surname>
, <given-names>K.</given-names>
</string-name>
;
<string-name><surname>Nakamura</surname>
, <given-names>H.</given-names>
</string-name>
<source xml:lang="en">Nat Struct Mol Biol</source>
<year>2003</year>
, <volume>10</volume>
, <fpage>980</fpage>
–<lpage>980</lpage>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0051"><label>51</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0051"><string-name><surname>Meng</surname>
, <given-names>E. C.</given-names>
</string-name>
;
<string-name><surname>Pettersen</surname>
, <given-names>E. F.</given-names>
</string-name>
;
<string-name><surname>Couch</surname>
, <given-names>G. S.</given-names>
</string-name>
;
<string-name><surname>Huang</surname>
, <given-names>C. C.</given-names>
</string-name>
;
<string-name><surname>Ferrin</surname>
, <given-names>T. E.</given-names>
</string-name>
<source xml:lang="en">BMC Bioinform</source>
<year>2006</year>
, <volume>7</volume>
, <fpage>339</fpage>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0052"><label>52</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0052"><string-name><surname>Hornak</surname>
, <given-names>V.</given-names>
</string-name>
;
<string-name><surname>Abel</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Okur</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Strockbine</surname>
, <given-names>B.</given-names>
</string-name>
;
<string-name><surname>Roitberg</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Simmerling</surname>
, <given-names>C.</given-names>
</string-name>
<source xml:lang="en">Proteins</source>
<year>2006</year>
, <volume>65</volume>
, <fpage>712</fpage>
–<lpage>725</lpage>
.
<pub-id pub-id-type="pmid">16981200</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0053"><label>53</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0053"><string-name><surname>Hinsen</surname>
, <given-names>K.</given-names>
</string-name>
<source xml:lang="en">J Comput Chem</source>
<year>2000</year>
, <volume>21</volume>
, <fpage>79</fpage>
–<lpage>85</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0054"><label>54</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0054"><string-name><surname>Jakalian</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Jack</surname>
, <given-names>D. B.</given-names>
</string-name>
;
<string-name><surname>Bayly</surname>
, <given-names>C. I.</given-names>
</string-name>
<source xml:lang="en">J Comput Chem</source>
<year>2002</year>
, <volume>23</volume>
, <fpage>1623</fpage>
–<lpage>1641</lpage>
.
<pub-id pub-id-type="pmid">12395429</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0055"><label>55</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0055"><string-name><surname>Stewart</surname>
, <given-names>J. J. P.</given-names>
</string-name>
<source xml:lang="en">J Mol Model</source>
<year>2012</year>
, <volume>19</volume>
, <fpage>1</fpage>
–<lpage>32</lpage>
.
<pub-id pub-id-type="pmid">23187683</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0056"><label>56</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0056"><string-name><surname>Case</surname>
, <given-names>D. A.</given-names>
</string-name>
;
<string-name><surname>Cheatham</surname>
, <given-names>T. E.</given-names>
</string-name>
;
<string-name><surname>Darden</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Gohlke</surname>
, <given-names>H.</given-names>
</string-name>
;
<string-name><surname>Luo</surname>
, <given-names>R.</given-names>
</string-name>
;
<string-name><surname>Merz</surname>
, <given-names>K. M.</given-names>
</string-name>
;
<string-name><surname>Onufriev</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Simmerling</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Wang</surname>
, <given-names>B.</given-names>
</string-name>
;
<string-name><surname>Woods</surname>
, <given-names>R. J.</given-names>
</string-name>
<source xml:lang="en">J Comput Chem</source>
<year>2005</year>
, <volume>26</volume>
, <fpage>1668</fpage>
–<lpage>1688</lpage>
.
<pub-id pub-id-type="pmid">16200636</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0057"><label>57</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0057"><string-name><surname>Word</surname>
, <given-names>J. M.</given-names>
</string-name>
;
<string-name><surname>Lovell</surname>
, <given-names>S. C.</given-names>
</string-name>
;
<string-name><surname>Richardson</surname>
, <given-names>J. S.</given-names>
</string-name>
;
<string-name><surname>Richardson</surname>
, <given-names>D. C.</given-names>
</string-name>
<source xml:lang="en">J Mol Biol</source>
<year>1999</year>
, <volume>285</volume>
, <fpage>1735</fpage>
–<lpage>1747</lpage>
.
<pub-id pub-id-type="pmid">9917408</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0058"><label>58</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0058"><string-name><surname>Silva</surname>
, <given-names>A. W. S.</given-names>
</string-name>
;
<string-name>, <surname>da Vranken</surname>
, <given-names>W. F.</given-names>
</string-name>
<source xml:lang="en">BMC Res Notes</source>
<year>2012</year>
, <volume>5</volume>
, <fpage>367</fpage>
<pub-id pub-id-type="pmid">22824207</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0059"><label>59</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0059"><string-name><surname>Heapy</surname>
, <given-names>A. M.</given-names>
</string-name>
;
<string-name><surname>Brimble</surname>
, <given-names>M. A.</given-names>
</string-name>
<source xml:lang="en">Tetrahedron</source>
<year>2010</year>
, <volume>66</volume>
, <fpage>5424</fpage>
–<lpage>5431</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0060"><label>60</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0060"><string-name><surname>Crane</surname>
, <given-names>S. N.</given-names>
</string-name>
;
<string-name><surname>Black</surname>
, <given-names>W. C.</given-names>
</string-name>
;
<string-name><surname>Palmer</surname>
, <given-names>J. T.</given-names>
</string-name>
;
<string-name><surname>Davis</surname>
, <given-names>D. E.</given-names>
</string-name>
;
<string-name><surname>Setti</surname>
, <given-names>E.</given-names>
</string-name>
;
<string-name><surname>Robichaud</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Paquet</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Oballa</surname>
, <given-names>R. M.</given-names>
</string-name>
;
<string-name><surname>Bayly</surname>
, <given-names>C. I.</given-names>
</string-name>
;
<string-name><surname>McKay</surname>
, <given-names>D. J.</given-names>
</string-name>
;
<string-name><surname>Somoza</surname>
, <given-names>J. R.</given-names>
</string-name>
;
<string-name><surname>Chauret</surname>
, <given-names>N.</given-names>
</string-name>
;
<string-name><surname>Seto</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Scheigetz</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Wesolowski</surname>
, <given-names>G.</given-names>
</string-name>
;
<string-name><surname>Massé</surname>
, <given-names>F.</given-names>
</string-name>
;
<string-name><surname>Desmarais</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Ouellet</surname>
, <given-names>M.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2006</year>
, <volume>49</volume>
, <fpage>1066</fpage>
–<lpage>1079</lpage>
.
<pub-id pub-id-type="pmid">16451072</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0061"><label>61</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0061"><string-name><surname>Paasche</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Zipper</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Schäfer</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Ziebuhr</surname>
, <given-names>J.</given-names>
</string-name>
;
<string-name><surname>Schirmeister</surname>
, <given-names>T.</given-names>
</string-name>
;
<string-name><surname>Engels</surname>
, <given-names>B.</given-names>
</string-name>
<source xml:lang="en">Biochemistry</source>
<year>2014</year>
, <volume>53</volume>
, <fpage>5930</fpage>
–<lpage>5946</lpage>
.
<pub-id pub-id-type="pmid">25196915</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0062"><label>62</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0062"><string-name><surname>Cleary</surname>
, <given-names>J. A.</given-names>
</string-name>
;
<string-name><surname>Doherty</surname>
, <given-names>W.</given-names>
</string-name>
;
<string-name><surname>Evans</surname>
, <given-names>P.</given-names>
</string-name>
;
<string-name><surname>Malthouse</surname>
, <given-names>J. P. G.</given-names>
</string-name>
<source xml:lang="en">BBA‐Proteins Proteom</source>
<year>2014</year>
, <volume>1844</volume>
, <fpage>1119</fpage>
–<lpage>1127</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0063"><label>63</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0063"><string-name><surname>Cheng</surname>
, <given-names>H. C.</given-names>
</string-name>
<source xml:lang="en">J Pharmacol Toxicol</source>
<year>2001</year>
, <volume>46</volume>
, <fpage>61</fpage>
–<lpage>71</lpage>
.
</mixed-citation>
</ref>
<ref id="bip22773-bib-0064"><label>64</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0064"><string-name><surname>Cheng</surname>
, <given-names>H. C.</given-names>
</string-name>
<source xml:lang="en">Pharmacol Res</source>
<year>2004</year>
, <volume>50</volume>
, <fpage>21</fpage>
–<lpage>40</lpage>
.
<pub-id pub-id-type="pmid">15082026</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0065"><label>65</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0065"><string-name><surname>Pastor</surname>
, <given-names>M.</given-names>
</string-name>
;
<string-name><surname>Pérez</surname>
, <given-names>C.</given-names>
</string-name>
;
<string-name><surname>Gago</surname>
, <given-names>F.</given-names>
</string-name>
<source xml:lang="en">J Mol Graph Model</source>
<year>1997</year>
, <volume>15</volume>
, <fpage>364</fpage>
–<lpage>371</lpage>
.
<pub-id pub-id-type="pmid">9704299</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0066"><label>66</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0066"><string-name><surname>Mou</surname>
, <given-names>T. C.</given-names>
</string-name>
;
<string-name><surname>Gille</surname>
, <given-names>A.</given-names>
</string-name>
;
<string-name><surname>Suryanarayana</surname>
, <given-names>S. R.</given-names>
</string-name>
<source xml:lang="en">Mol Pharmacol</source>
<year>2006</year>
, <volume>70</volume>
, <fpage>878</fpage>
–<lpage>886</lpage>
.
<pub-id pub-id-type="pmid">16766715</pub-id>
</mixed-citation>
</ref>
<ref id="bip22773-bib-0067"><label>67</label>
<mixed-citation publication-type="journal" id="bip22773-cit-0067"><string-name><surname>Tomic</surname>
, <given-names>S.</given-names>
</string-name>
;
<string-name><surname>Nilsson</surname>
, <given-names>L.</given-names>
</string-name>
;
<string-name><surname>Wade</surname>
, <given-names>R. C.</given-names>
</string-name>
<source xml:lang="en">J Med Chem</source>
<year>2000</year>
, <volume>43</volume>
, <fpage>1780</fpage>
–<lpage>1792</lpage>
.
<pub-id pub-id-type="pmid">10794695</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000E56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Pmc |étape= Corpus |type= RBID |clé= PMC:7159131 |texte= Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza‐decaline scaffold }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:26572934" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |